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The sarcoglycanopathies are a subset of the limb girdle muscular dystrophies (LGMD) 
caused by mutations in the sarcoglycan genes (α, β, γ and δ).  In collaborative studies, δ-
sarcoglycan was delivered to deficient hamsters using a recombinant adeno-associated virus 
(AAV), which rescued muscle biochemically, histologically, and functionally.  Murine 
knockouts for the other sarcoglycans permitted us to pursue AAV-mediated gene delivery.  
AAV-mediated gene delivery of β-sarcoglycan to deficient mice provided long-term biochemical 
and histological rescue.  AAV-mediated gene delivery of α-sarcoglycan to deficient mice 
showed initial rescue of biochemical and histological defects, although expression was not 
persistent.  Severe Combined Immune-Deficient (SCID) mouse studies indicated that α-
sarcoglycan over-expression leads to cytotoxicity.  The apparent cytotoxicity can be interpreted 
with emerging models of sarcoglycan complex assembly.  These studies show that AAV-
mediated delivery of even closely related proteins can lead to different outcomes, and aspects of 
protein biochemistry can alter efficacy of gene delivery. 
 Inherited muscle disorders typically have defined primary biochemical defects.  
However, there are likely secondary responses that mitigate gene delivery success.  To dissect 
such variables, we studied the immunostimulatory properties of dystrophic muscle.  We 
hypothesized that immune cell infiltrate accompanying degeneration/regeneration could be 
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 immunostimulatory, which could elicit an immune response to delivered transgenes, hampering 
the success of gene delivery.  To study this, we tested antibody response to and persistence of, β-
galactosidase in normal and dystrophic muscle.  Consistent with our hypothesis, dystrophic 
muscle showed increased immune surveillance and recognition of β-galactosidase, evidenced by 
antibody titers and clearance of transduced cells.  Furthermore, biochemical rescue of the 
dystrophy quenched the immune response.  This indicated that dystrophic muscle is more prone 
to immune responses and that aspects of tissue pathology influence the persistence and efficacy 
of gene delivery.  Our results suggest that full biochemical rescue will attenuate 
immunostimulatory effects.   
 We also address a hurdle facing AAV-mediated gene therapy; namely, delivery methods.  
We developed an injection manifold, which was used to safely, accurately, and consistently 
deliver genes to 20 mm2 regions of muscle.   
 Taken together, these results more clearly define barriers to gene delivery.  Future 
research will finely tune regulation of transgenes and enable full rescue of biochemical defects. 
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Introduction 
 
 1
 1.1 Limb-girdle muscular dystrophies 2C, 2D, 2E and 2F, the sarcoglycanopathies 
Four forms of limb-girdle muscular dystrophy (LGMD 2D, 2E, 2C, and 2F) are caused 
by mutations in any one of the four genes encoding the dystrophin-associated sarcoglycan 
proteins (α, β, γ, and δ).  These four limb-girdle muscular dystrophies are a group of genetically 
heterogeneous autosomal recessive muscular dystrophies (Lim et al. 1995; Ozawa et al., 1995; 
Bonnemann et al. 1996a; Bonnemann et al. 1996b; Duggan and Hoffman 1996; Jung et al. 
1996a; Jung et al. 1996b; Nigro et al. 1996; Piccolo et al. 1996; Sewry et al. 1996; Dincer et al. 
1997; Quinlivan et al. 1997).  Mutations in any one of the four sarcoglycan genes, termed the 
“primary sarcoglycanopathies,” lead to a secondary biochemical deficiency in all of the other 
sarcoglycan proteins (Jung et al. 1996a; Ozawa et al., 1998).  This secondary loss is now thought 
to occur post-translationally, potentially due to inaccurate assembly and stabilization of the 
dystrophin-associated protein complex (Chen et al. 2000).  The disease presentation and 
progression of the sarcoglycanopathies are similar to that of Duchenne muscular dystrophy, and 
patients with primary sarcoglycanopathies are clinically indistinguishable from those with 
primary dystrophinopathies.  Approximately 10-20% of cases with a Duchenne muscular 
dystrophy phenotype but normal dystrophin findings by muscle biopsy are caused by 
sarcoglycan gene mutations.  The relative occurrence for each of the different 
sarcoglycanopathies in the American/European population is α > β >  γ  > δ  in about a 6:3:2:1 
ratio (Duggan et al. 1997a).   
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 1.2 The Sarcoglycan Proteins 
 Alpha, beta, gamma, and delta sarcoglycans are single-pass transmembrane glycoproteins 
that assemble stoichiometrically to form a tetrameric sarcoglycan complex (Yamamoto et al. 
1993; Yoshida et al. 1997; Yoshida and Ozawa 1990; Yoshida et al. 1994).  This complex is one 
of the components of the dystrophin-glycoprotein complex located at the myofiber plasma 
membrane (Figure 1) (Ervasti et al. 1990).  The sarcoglycans are all N-glycosylated with large 
extra-cellular domains containing cysteine clusters and short intra-cellular domains.  α-, γ- and δ-
sarcoglycan are primarily expressed in striated muscle, while β-sarcoglycan is moderately 
expressed in other tissues as well (Bonnemann et al. 1995; Lim et al. 1995; Jung et al. 1996; 
Nigro et al. 1996; Roberds et al. 1993a; Noguchi et al. 1995).   
Investigation of the assembly of the sarcoglycan complex revealed that the four 
transmembrane proteins are synthesized in the rough endoplasmic recticulum (ER) and 
glycosylated in both the ER and Golgi apparatus.  The individual sarcoglycans are then 
assembled in the Golgi to form the sarcoglycan complex, which further assembles with other 
dystrophin associated protein complexes that are all transported to the cell surface.  A 
hierarchical order of assembly has been established with β-sarcoglycan nucleating the complex. 
The tetramer is completed by subsequent addition of  γ- or δ-sarcoglycan added in either order, 
and followed by the addition of α-sarcoglycan (Noguchi et al. 2000).  Prior to the elucidation of 
the assembly of the sarcoglycan complex, Holt and Campbell (1998) used myc-tagged 
sarcoglycan proteins in a heterologous expression system and found that efficient and correct 
targeting of the sarcoglycan complex could only be completed with the expression of all four 
sarcoglycan proteins. 
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 The sarcoglycans are believed to interact with both the dystroglycans and dystrophin.  δ-
sarcoglycan is thought to interact directly with dystroglycan (Vainzof et al. 1996; Sakamoto et 
al. 1997; Chan et al. 1998), while the complete complex interacts with the C-terminus of 
dystrophin (Suzuki et al. 1994; Ozawa et al. 1998; Suzuki et al. 1992; Ahn and Kunkel 1995; 
Rafael et al. 1996; Yang et al. 1995;  Jung et al. 1995; Duclos et al. 1998; Araishi et al. 1999; 
Iwata et al. 1993; Roberds et al. 1993a).  These interactions have provided some of the first clues 
to the function of the sarcoglycan complex.   
Although the sarcoglycan complex may help stabilize the interactions of dystrophin and 
the dystroglycans, contributing to the structural integrity of the myofiber plasma membrane 
during contraction-induced mechanical stress (Suzuki et al. 1994; Ozawa et al. 1998; Araishi et 
al. 1999; Hack et al. 2000; Yoshida et al. 2000), however, this stabilization may not be the only 
function of the sarcoglycan complex.  Database searches revealed homology of the sarcoglycans 
to a number of epidermal growth factor-like (EGF-like) domains of receptors, a nerve growth 
factor receptor, and a low-density lipoprotein receptor.  The sarcoglycans are arranged at the 
membrane so that these EGF-like domains are extracellular, which would enable them to interact 
with a ligand (Ibraghimov-Beskrovnaya et al. 1992).  The sarcoglycan phosphorylation sites are 
located cytoplasmically (Bonnemann et al. 1995; Lim et al. 1995; Noguchi et al. 1995; Roberds 
et al. 1993a), which may imply a role in signal transduction.  Betto et al. (1999) has also shown 
that α-sarcoglycan can act as an ecto-ATPase.  Therefore, deficiencies in α-sarcoglycan may 
compromise the ability of myofibers to protect themselves against extracellular ATP, which in 
turn could regulate the activity of purinergic receptors and may have a role in potential calcium 
dysregulation.  In addition, the sarcoglycan proteins may also interact with a calcium channel.  
Therefore the sarcoglycan proteins could play a role in the regulation of calcium as they are well 
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 positioned at the plasma membrane to directly or indirectly control the influx of calcium (Hack 
et al. 2000).  There has also been an interaction observed between the integrins and the 
sarcoglycans, which could indicate a role in the bi-directional signaling and regulation of the 
α5β1 integrin in striated muscle (Yoshida et al. 1998).  Thus, deficiencies in the sarcoglycans 
could disrupt the proper coupling between signaling and mechanical complexes in muscle (Hack 
et al. 2000).   
1.2.1 α-sarcoglycan  
 The α-sarcoglycan gene was first cloned in rabbit (Roberds et al. 1993a) and was later 
localized in humans to chromosome 17q21 (McNally et al. 1994).  The human genomic DNA 
covers over 5.4 kb and contains 10 exons (Roberds et al. 1994), while the human cDNA 
comprises 1410 base pairs (bp), which includes an open reading frame of 1161 bp encoding 387 
amino acids (Roberds et al. 1993a).  The predicted weight is 42.9 kD, although the native protein 
weighs about 50 kD (Yoshida and Ozawa 1990; Ervasti and Campbell 1991).    Initially, the 
protein was called adhalin (“adhal” in Arabic means muscle) as patients suffering from severe 
childhood autosomal recessive muscular dystrophy (SCARMD) (prevalent in Arabic countries) 
were missing this protein (Roberds et al. 1993a).  α-sarcoglycan is a Type I transmembrane 
protein with an amino-terminal signal sequence, two consensus sites for phosphorylation (one 
Ca2+-calmodulin protein kinase site Ser377 and one casein kinase II site Thr336), a single-pass 
transmembrane domain, two predicted N-linked glycosylation sites (Asn174 and Asn246), a 
cytoplasmic carboxyl-terminus, five extracellular cysteine residues, and an ATP binding site in 
the extracellular domain (Betto et al. 1999) (Figure 2).  α-sarcoglycan is primarily expressed in 
striated muscle, but low amounts are detected in the bladder, lung, and small intestine (Roberds 
et al. 1993a; Roberds et al. 1994). 
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 1.2.2 β-sarcoglycan 
 The human β-sarcoglycan gene is located on 4q12 and spans about 13.5 kb of genomic 
DNA containing 6 exons (Bonnemann et al. 1996b).  The human cDNA for this gene is 1225 bp 
with an open reading frame of 956 bp that encodes 318 amino acids (Bonnemann et al. 1995; 
Lim et al. 1995).  The predicted weight is 34.8 kD, with the native protein weighing 43 kD.  β-
sarcoglycan is a type II transmembrane protein with a short N-terminal cytoplasmic domain 
containing a large hydrophobic region, a potential protein kinase C phosphorylation site (Ser21), 
a single transmembrane region, a large extracellular domain (C-terminal), five extracellular 
cysteine residues, three potential N-linked glycosylation sites (Asn158, Asn211 and Asn258) (Figure 
2).  β-sarcoglycan is expressed most abundantly in striated muscle, but can also be found in 
brain, liver, kidney, lung, placenta, and adult pancreas (Lim et al. 1995; Bonnemann et al. 
1996b).   
1.2.3 γ-sarcoglycan 
 The human γ-sarcoglycan gene is located on 13q12 and spans over 100 kb of genomic 
DNA containing 8 exons (McNally et al. 1996).  The human cDNA open reading frame consists 
of 873 bp that encodes 290 amino acids (Noguchi et al. 1995).  The predicted weight is 32 kD, 
while the native protein weighs 35 kD (Ervasti et al. 1990; Yoshida and Ozawa 1990).  γ-
sarcoglycan is a type II transmembrane protein with a large extracellular domain (C-terminal), a 
potential N-linked glycosylation site (Asn110), and five conserved cysteine residues, a single 
transmembrane domain, one potential phosphorylation site (Yoshida et al. 1998), and a short 
intracellular domain (Noguchi et al. 1995) (Figure 2).  γ-sarcoglycan is expressed exclusively in 
striated muscle (Noguchi et al. 1995).  
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 1.2.4 δ-sarcoglycan 
 The human δ-sarcoglycan gene is located on 5q33-q34, spanning over 100 kb of genomic 
DNA with 8 exons.  The human cDNA has an open reading frame of 870 bp encoding 290 amino 
acids (Nigro et al. 1996).  The predicted molecular weight is 32 kD with a native weight of 35 
kD (Yoshida et al. 1997).  δ-sarcoglycan is a type II transmembrane protein with a short 
cytoplasmic domain (N-terminal), a single transmembrane domain, a large extracellular domain, 
five cysteine residues, and three potential N-linked glycosylation sites (Asn61, Asn109 and Asn285) 
(Figure 2).  It differs from the other sarcoglycans, as it does not appear to have any 
phosphorylation site.  However, δ-sarcoglycan and γ-sarcoglycan have the highest amino acid 
homology among the sarcoglycans, with 55% amino acid identity and 70% amino acid similarity 
(Nigro et al. 1996).  It is believed that one of these two sarcoglycans originated by way of a gene 
duplication event of the other (McNally et al. 1996; Nigro et al. 1996).  δ-sarcoglycan is 
expressed predominantly in striated muscle, with an alternate splice variant (utilizing an 
alternative exon 8 which lacks the conserved cysteine residues) expressed outside of muscle 
(Jung et al. 1996).   
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 1.3 Sarcoglycan deficient animal models 
 Animal models for all four of the sarcoglycanopathies are now available for study.  The 
first model to be identified was a naturally occurring hamster model for δ-sarcoglycanopathy.  
However, since the identification of the gene defect in the hamster, there has been the subsequent 
production of knockout mouse models for each of the sarcoglycan deficiencies including δ-
sarcoglycan.  Two different groups have generated a knockout model for each of the 
sarcoglycans, except δ-sarcoglycan, which only has one mouse model.  This duplication in 
production may lead to discrepancies between the knockout models, as different areas of each 
sarcoglycan gene were disrupted in the two models.  These discrepancies create the opportunity 
for genotype/phenotype differences; however, as all knockouts generated have demonstrated no 
protein production from the null allele, it is likely that any discrepancy between knockout models 
is not due to the type of knockout generated.  Each knockout strain is addressed below in greater 
detail.  
1.3.1 α-sarcoglycan deficient mice 
 Two separate groups have reported the generation of α-sarcoglycan deficient mice 
(Duclos et al. 1998; Liu and Engvall 1999).  Both models for this disease show a progressive 
muscular dystrophy.  More specifically described in Duclos et al. (1998), these mice exhibit the 
muscular dystrophy hallmarks of muscle fiber necrosis, degeneration/regeneration, central 
nucleation, atrophy, hypertrophy, fiber splitting, and endomysial fibrosis.  The two groups 
generated their mice slightly differently, by targeting different exons of the α-sarcoglycan gene.  
Duclos et al. (1998) knocked out exons 2 and 3 with a neomycin resistance gene.  These two 
exons were targeted because they are the location of one third of the mutations in human 
patients.  However, the mutation did not eliminate the N-terminal signal sequence. Liu and 
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 Engvall (1999), on the other hand, disrupted exons 1 and 2 to delete the N-terminal signal 
sequence and both exons.  Both groups describe the generation of mutations in the α-sarcoglycan 
gene that created null alleles (Duclos et al. 1998; Liu and Engvall 1999). 
Duclos et al. (1998) indicate that Southern blot analysis showed homologous 
recombination, and northern blot analysis revealed an absence of full-length coding sequence in 
skeletal and heart muscle.  However, RT-PCR analysis indicated a minor transcript, which is the 
result of using a cryptic splice site in the neomycin cassette.  Sequencing of this product revealed 
that it encoded exon 1 and 516 bp from the inverted neomycin cassette spliced into exon 4.  This 
splice event inserted 172 amino acids from the neomycin cassette and maintained a reading 
frame with exon 4 to finish the rest of the α-sarcoglycan protein. However, this transcript would 
result in a protein lacking 91 amino acids encoded by exons 2 and 3, including part of the signal 
sequence.  Analysis of cardiac and skeletal muscle to identify production of the mutant protein 
by immunoblot or immunofluorescence with the use of a C-terminal peptide antibody against α-
sarcoglycan did not find any mutant protein.  α-sarcoglycan protein was absent from the 
membranes of both cardiac and skeletal muscle.  The α-sarcoglycan deficiency leads to a 
dramatic reduction of sarcospan, β-, γ- and δ-sarcoglycan with a slight reduction of α-
dystroglycan and patchy staining of dystrophin at the sarcolemma.  In addition, there is a ~10- 
fold increase in serum creatine kinase (CK) activity compared with control animals (Duclos et al. 
1998).  
Liu and Engvall (1999) did not describe the analysis of the mice in as much detail as 
Duclos et al.(1998).  However, Southern blot analysis verified disruption of the α-sarcoglycan 
gene.  Immunofluorescence and immunoblot analysis showed no expression of α-sarcoglycan in 
homozygous knockout animals, and consistent with Duclos et al.(1998), there was a significant 
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 decrease in β-, γ- and δ-sarcoglycan present at the sarcolemma, resulting in a progressive 
muscular dystrophy phenotype (Liu and Engvall 1999).   
1.3.2 β-sarcoglycan deficient mice 
 Two groups have also described the generation of β-sarcoglycan knockout mice, which 
develop a progressive muscular dystrophy (Araishi et al. 1999; Durbeej et al. 2000).  Araishi et 
al. (1999) was the first group to describe the generation of such mice.  This model has targeted 
disruption of exon 2 of the β-sarcoglycan gene with a neomycin gene.  Exon 2 contains the 
intracellular and membrane spanning domains of the β-sarcoglycan protein.  Durbeej et al. 
(2000) targeted exons 3, 4, 5 and 6 of β-sarcoglycan, which encode part of the transmembrane 
domain and some of the extracellular portion of the protein.  They utilized  the phosphoglycerate 
kinase promoter and neomycin phosphotransferase cDNA for disruption of the β-sarcoglycan 
gene.  Both groups describe the successful generation of null alleles.     
 Araishi et al.(1999) first confirmed disruption of exon 2 with a single copy of the 
neomycin gene by Southern blot analysis.  The creation of a null allele was verified by northern 
blot analysis and western blot analysis.  The results showed the absence of β-sarcoglycan mRNA 
in the homozygous mutant mice.  The western blot revealed that there was no β-sarcoglycan 
protein detected.  Immunofluorescence analysis of these animals showed deficiencies in all of the 
other sarcoglycan proteins and sarcospan.  These mice also exhibited a number of pathologic 
hallmarks in muscle associated with the muscular dystrophies, such as infiltration of 
mononuclear cells, degenerating/regenerating fibers, centrally located nuclei, increased 
connective tissue proliferation, and necrotic fibers with phagocytosis.  Serum CK levels were 
increased up to ~100 times normal levels.  All of these observations confirmed the hypothesis 
that a progressive muscular dystrophy phenotype is present in this β-sarcoglycan deficient 
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 mouse.  This group went on to show that using wheat germ agglutinin (WGA) affinity 
chromatography there is a decrease in the amount of the dystrophin-dystroglycan complex 
isolated from the β-sarcoglycan deficient mice when compared with controls.  This indicates that 
deficiencies in the sarcoglycan-sarcospan complex may cause instability in the dystrophin-
dystroglycan complex  (Araishi et al. 1999). 
 Using Southern blot analysis, Durbeej et al. (2000) confirmed the disruption of exons 3-6 
in their model with the single homologous recombination of the phosphoglycerate kinase 
promoter and neomycin phosphotransferase cDNA.  Northern blot analysis revealed no β-
sarcoglycan transcripts were present in skeletal muscle of the β-sarcoglycan deficient animals.  
Using a specific probe for exon 2, small amounts of a shorter transcript, of the 4.0 kb β-
sarcoglycan transcript were present.  However, upon analysis of microsome preparations, from 
skeletal muscle, cardiac muscle, and lung tissue, with antibodies specific to amino acids in exons 
1 and 2, this shorter product was not detected.  Additionally, the absence of β-sarcoglycan in 
skeletal muscle, cardiac muscle and smooth muscle was confirmed by immunofluorescence.  
These β-sarcoglycan deficient mice demonstrated elevated serum CK levels and a progressive 
muscular dystrophy with the findings in muscle of large areas of focal necrosis, central nuclei, 
fiber splitting, hypertrophy, extensive dystrophic calcification, endomysial fibrosis, and fatty 
infiltration.  This group found that these muscles were much more severely affected than the α-
sarcoglycan deficient animals they had generated previously (Duclos et al. 1998).  
Immunofluorescence confirmed that the other sarcoglycans and sarcospan were concomitantly 
reduced, as was seen in the β-sarcoglycan deficient mice generated by Araishi et al. (1999).  
Durbeej et al. (2000) went on to show that the sarcoglycan-sarcospan complex is reduced in 
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 cardiac muscle of their β-sarcoglycan deficient mice.  In addition to the progressive muscular 
dystrophy, these mice also developed a marked cardiomyopathy (Durbeej et al. 2000).  
1.3.3 γ-sarcoglycan deficient mice 
 There has only been one group to publish the generation of a γ-sarcoglycan deficient 
mouse (Hack et al. 1998), although a second group has successfully generated another γ-
sarcoglycan deficient mouse and are currently working on the manuscript (personal 
communication, T. Sasaoka).  Hack et al. (1998) describe the γ-sarcoglycan deficient mouse as 
suffering from a progressive muscular dystrophy.  They targeted exon 2, which contains the 
initiator methionine, the cytoplasmic tail, and the transmembrane domain of the γ-sarcoglycan 
gene, using the phosphoglycerate kinase promoter and neomycin phosphotransferase cDNA.  
They confirmed single copy homologous recombination by Southern blot analysis.   Immunoblot 
analysis was used to show that there was no production of γ-sarcoglycan, verifying the 
generation of a null allele.  In addition to the primary deficiency of γ-sarcoglycan, there is also a 
secondary deficiency seen by immunofluorescence in these mice of both the β- and δ-
sarcoglycan mice with only partial retention of α-sarcoglycan.   Hack et al. (1998) also show that 
the γ-sarcoglycan deficient mice suffered from a cardiomyopathy, which results in death of 50% 
of these mice by 5 months of age.   In addition, these mice have elevated CK levels and 
pathologic changes in muscle, characteristic of progressive muscular dystrophy, comprising fiber 
size variation, including fiber hypertrophy, degeneration/regeneration, central nuclei, 
inflammatory infiltrate, abnormal calcification, and increased fatty and fibrous connective tissue 
(Hack et al. 1998).   
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 1.3.4 δ-sarcoglycan deficient animals 
 The Bio 14.6 hamster has been studied since the 1960’s when it was first identified as an 
animal model for cardiomyopathy (Homburger et al. 1962; Homburger et al. 1963).  However, 
the cause of both its cardiomyopathy and muscular dystrophy was unknown for over three 
decades.  Phenotypically, these hamsters present with muscle necrosis and undergo subsequent 
rounds of muscle fiber degeneration/regeneration, leading to central nucleation (Homburger et 
al. 1962; Homburger et al. 1963).  A deficiency in the Bio 14.6 hamsters of α-sarcoglycan was 
found to be present before the onset of myocytolysis (Roberds et al. 1993b; Mizuno et al. 1995).  
However, it was not until 1997 that Nigro et al. (1997) discovered that both the cardiomyopathy 
and muscular dystrophy were caused by a deficiency in the δ-sarcoglycan gene.  Nigro et al. 
(1997) established that the progressive muscular dystrophy seen in the Bio 14.6 hamster was due 
to a deletion of the promoter region and exon 1 of the δ-sarcoglycan gene.  mRNA expression of 
δ-sarcoglycan is slight (<3-5% of normal levels) in heart and negligible in skeletal muscle.    The 
Southern blot analysis revealed a deletion in the first exon of δ-sarcoglycan.  Linkage analysis 
was used to verify that the deletion in the δ-sarcoglycan gene caused both the cardiomyopathy 
and muscular dystrophy (Nigro et al. 1997).   
A recently described δ-sarcoglycan deficient mouse was generated by replacing exon 2 of 
the δ-sarcoglycan gene, which contains 63 amino acids of the cytoplasmic domain and the entire 
transmembrane domain, with a neomycin resistance gene (Coral-Vazquez et al. 1999).  
Homologous recombination was confirmed by Southern blot analysis, and northern blot analysis 
revealed that there were no transcripts containing exon 2 of δ-sarcoglycan in skeletal muscle.  
However, RT-PCR analysis showed a product, which was an alternative splicing of exon 1 to 
exon 3, maintaining the open reading frame from exon 3 to exon 8.  Translation of this smaller 
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 transcript was not detected by western blot analysis in skeletal or cardiac muscle.  
Immunofluorescence revealed a secondary loss of the entire sarcospan-sarcoglycan complex.  
These mice also displayed a 15-20 fold increase in CK levels and some of the pathologic 
hallmarks of muscular dystrophies, such as muscle fiber necrosis, degeneration/regeneration, 
centrally placed nuclei, endosomal fibrosis, fiber splitting, hypertrophy, dystrophic calcification, 
and fatty infiltration.  A cardiomyopathy observed is the δ-sarcoglycan deficient mice was 
similar to that found in the Bio 14.6 hamster (Coral-Vazquez et al. 1999).      
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 1.4 The Adeno-associated Virus 
 The adeno-associated virus (AAV) is a member of the parvovirus family (Lukashov and 
Goudsmit 2001).  The single-stranded DNA genome of AAV is comprised of ~ 5,000 bases, and 
consists of two genes, rep and cap, driven by three promoters, and flanked by two inverted 
terminal repeat sequences (Berns 1990).   The inverted terminal repeats (ITRs) are 145 bases 
long.  The first 125 bases of each repeat is palindromic sequence that is expected to self-base pair 
to form a T- or Y- shaped secondary structure, depending on the hybridization of two internal 
palindromes, flanked by a more extensive palindrome.  The folded configuration contains only 
seven unpaired bases, six that enable the internal palindromes to fold and the seventh separates 
the two internal palindromes.  The inverted terminal repeats are necessary for encapsidation of 
AAV’s genome and are also critical for integration into the host genome (Wang et al. 1997).   
Replication of AAV involves a series of important features.  First, the inverted terminal 
repeats act as primers during AAV DNA replication.  Second, AAV is thought to have a single-
strand displacement mechanism for DNA synthesis and therefore there is no lagging strand 
synthesis.  Finally, current replication models predict site-specific cleavage of replicative 
intermediates; however, the putative DNAses involved in this process have not been identified, 
and are presumed to be of cellular origin (Berns 1990).    
The AAV virion has three coat proteins, encoded by the cap genes.  The three proteins 
are VP-1 at 87 kilodaltons, VP-2 at 73 kilodaltons, and VP-3 at 62 kilodaltons (Wistuba et al. 
1995).  Comparative tryptic digestions of all three proteins give very similar patterns, indicating 
that all three proteins were determined by a common DNA sequence (Berns 1990); this has been 
verified by DNA and RNA studies of the virus (Wistuba et al. 1995).  In addition, the coat 
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 proteins also appear to be coded by overlapping DNA sequences.  There is no evidence that any 
of the coat proteins are glycosylated (Berns 1990).   
Of all the parvoviruses, AAV is the most dependent upon the intracellular milieu for 
replication.  The other parvoviruses require host cells to go through S phase in order to replicate.  
However, AAV requires adeno- or herpesvirus co-infection of host cells in order for it to 
undergo replication and a productive infection.  The adenovirus genes that are required for AAV 
to undergo an active infection include E1a, E1b, E2a, and E4 (Janik et al. 1981).  E1a is required 
due to its activation of other adenovirus early genes.  E1b has also been identified as necessary 
for AAV DNA replication to occur, but it does not appear that there is a correlation between 
AAV transcript accumulation and the introduction of E1b.  E2a encodes a DNA binding protein 
that is required for adenovirus DNA synthesis.  However, it is not necessary for AAV DNA 
synthesis, although AAV’s DNA synthesis is severely hampered by mutations in the E2a gene.  
E4 appears to be involved in encoding a helper function protein required for DNA replication of 
AAV (Berns 1990).  No adenovirus late genes appear to be required for AAV particle 
production.   
The rep gene encodes proteins that are required for both transcription and DNA 
replication of AAV.  It has been demonstrated that rep performs a trans-activation role by 
initiation of transcription (Tratschin et al. 1986; Hermonat et al. 1998).  It also appears that AAV 
can use its rep gene to regulate its own gene expression as well as the helper virus.  In the 
absence of a permissive intracellular environment, there is a low level of rep expression, which 
inhibits normal levels of AAV gene expression.  Transcription is suppressed as rep gene 
transcripts inhibit a number of heterologous promoters, including at least one, if not all, of the 
rep and cap promoters.  These diminished levels of transcription can be overcome by co-
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 infection with a helper virus.  Therefore, AAV gene expression appears to be autoregulated both 
in a positive and a negative fashion (Berns 1990).    
AAV requires other helper viruses, such as adenovirus, to undergo its reproductive cycle.  
Much of the machinery needed for a productive infection is derived from the helper virus and the 
host cell.  It is thought that because AAV takes away the replication machinery from the helper 
virus, AAV may be able to attenuate replication of the helper virus (Alexander et al. 1997; 
Barresi et al. 1997).  Indeed, some reports have suggested that AAV may protect against the 
development of some virally-induced diseases such as cervical cancer (Sprecher-Goldberger et 
al. 1971; Mayor et al. 1976; Georg-Fries et al. 1984; Coker et al. 2001) and polymyositis (Tezak 
et al. 2000).  In addition, most human populations appear to be infected with AAV, with 80-90% 
testing seropositive for the virion in the first two years of life (Berns and Linden 1995) with no 
association with disease.  Therefore, AAV is not associated with disease and may even be 
protective against disease.  
The potentially beneficial nature of AAV, its relatively wide tropism, and its apparent 
non-pathogenic nature has made it a prime candidate as a gene delivery vehicle (Gertz 1973).  
AAV also appears able to transduce cells and maintain transgene expression with little or no 
cytotoxicity  (Berns and Bohenzky 1987; Gaschen et al. 1992; Flotte et al. 1993; Clark et al. 
1995; Afione et al. 1996; Dong et al. 1996; Chen et al. 1997; Clark et al. 1997).  Another 
potential advantage of AAV is its ability to integrate stably into host chromosomes during its 
latent life cycle, via inverted terminal repeats.  Integration is permissive for long-term expression 
of transgenes introduced into the virus backbone.   
It appears that the wild-type genome integrates preferentially near or into a specific 
muscle gene (troponin T, TNNT1) on chromosome 19 (Dutheil et al. 2000).  It was reported that 
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 muscle tissue appears to be a site of infection and latency of wild-type AAV (Tezak et al. 2000).  
Both reports suggested that muscle tissue would be an excellent target for AAV-mediated gene 
delivery.  While some early observations indicated that AAV was unable to transduce non-
dividing cells (Berns and Linden 1995; Fisher-Adams et al. 1996), there has been some 
convincing in vivo evidence showing that it does transduce non-dividing cells.   Transduction of 
non-dividing cells was shown in a variety of tissues, including mouse and rat muscle (Xiao et al. 
1996; Greelish et al. 1999; Li et al. 1999), rat brain (Chen et al. 1997), and pig heart (Clark et al. 
1997).  We and others have also been able to show that AAV is able to infect both mature and 
immature muscle (Kessler et al. 1996; Fisher et al. 1997; Snyder et al. 1997; Li et al. 1999; 
Pruchnic et al. 2000).  AAV’s ability to infect muscle easily is possibly due to muscle’s high 
expression of heparin sulfate proteoglycan (HSP) (Pruchnic et al. 2000; Cao et al. 2001), which 
is an attachment receptor for AAV (Summerford and Samulski 1998) and the expression of 
integrin αVβ5 in muscle (Pruchnic et al. 2000), which is a second co-receptor for AAV 
(Summerford et al. 1999).  AAV is also able to bypass the basal lamina that surrounds muscle 
fibers, while adenovirus and herpes virus cannot (Feero et al. 1997).  The basal lamina has pores 
that are 40 nm (Yurchenko 1990), and because the AAV particle is only 20 nm in diameter, it is 
easily able to pass through these pores, while adenovirus at 70-100 nm and herpes at 120-300 nm 
cannot.   
AAV’s small size is also a major disadvantage for gene delivery purposes, as 
recombinant AAV has only a 5 kb DNA carrying capacity.  This limitation makes it impossible 
to encode the full-length dystrophin cDNA, which would be ideally used to treat Duchenne 
muscular dystrophy.  However, all of the sarcoglycans have coding sequences that are less than 2 
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 kb, making the sarcoglycanopathies an excellent system for testing the efficacy of AAV-
mediated gene therapy.   
 Advances in AAV production technology have facilitated the availability of a three 
plasmid transfection method for producing recombinant AAV, without helper virus 
contamination (Xiao et al. 1998) (Figure 3).  This method utilizes one plasmid for the helper 
functions normally supplied by the adenovirus or other helper virus, one that contains the 
essential AAV genes necessary for viral capsid production, and a final plasmid with the gene of 
interest flanked by the ITRs.  The 145 basepair cis-acting sequences of the ITRs are the only 
viral sequences necessary for integration and packaging of DNA into AAV virions.  As the ITRs 
are the only viral sequence remaining in the AAV vector, AAV is replication deficient and has 
little or no chance of regenerating wild-type AAV or adenovirus during the production of the 
virus (During et al. 1998).  The triple plasmid transfection method provides AAV titers of up to 
1010 or 1011 transducing units (t.u.)/mL, not dissimilar to those obtained with wild-type AAV 
propagation (Figure 3).   
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 1.5 AAV gene delivery as a therapeutic potential for other diseases 
 AAV’s ability to transduce non-dividing cells with no overt pathological consequences 
has made it an attractive vector for a number of other non-muscle related diseases.  Some of the 
earliest work with the AAV vector was done with cystic fibrosis, including the first in vivo gene 
transfer using this vector in 1993 and the first phase I clinical trial using AAV in 1996.  As of 
2001, there are two ongoing phase I clinical trials using AAV to treat CF, both of which have 
shown no untoward inflammatory responses to date.  Use of AAV in CF patients has not yet 
shown clinical efficacy, due to the inefficiency of the route of delivery, the difficulty in 
transducing lung stem cells, and the lack of DNA capacity to package an optimal promoter 
(Flotte and Laube 2001).   
All other AAV work reported to date has involved animal models of a variety of human 
diseases.  Two genes, tyrosine hydroxylase (TH) and aromatic L-amino acid decarboxylase 
(AADC), have been investigated as means of experimental therapeutics for Parkinson’s disease 
in the (6-OHDA)-lesioned parkinsonian rat model.  When these genes are co-delivered by intra-
cranial injection, they appear able to exhibit a behavioral recovery in the rat model (Ozawa et al. 
2000).  In addition, recent data has suggested that protection of dopaminergic neurons in the 
substantia nigra is possible by using AAV-mediated gene delivery of a glial cell line-derived 
neurotrophic factor (GDNF) gene to neurons (Bjorklund et al. 2000).  AAV has also been 
applied to animal models of cardiovascular disease.  A recent report described AAV delivery of 
antisense (AS) DNA of the angiotensinogen, angiotensin type I receptor (AT1-R) and angiotensin 
converting enzyme genes, which are all associated with vasoconstrictive properties.  A single 
dose of AAV-AS-AT1-R resulted in significantly prolonged reduction of blood pressure (Phillips 
et al. 1997; Phillips et al. 2000).   
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 Perhaps the most studied application of AAV to human disease has been with regards to 
clotting abnormalities, specifically Hemophilia B (deficiency of Factor IX).  Factor IX’s cDNA, 
being only 1.4 kb, easily fits into the AAV vector.  This is in contrast to the more common 
Hemophilia A, where the causative Factor VIII cDNA is too large to be packaged by AAV.  
Factor IX is a secreted protein and readily equilibrates between extravascular and intravascular 
space, such that there is no prerequisite for Factor IX being delivered directly into the 
circulation.  This has permitted the application of intramuscular administration of AAV for 
delivery of the gene and protein (Chuah et al. 2001).  Work with Factor IX has led to a phase I 
clinical trial, and a recent report suggests that there is no toxicity or germline transduction and no 
formation of inhibitory antibodies against Factor IX; each of these are important aspects of 
proving vector safety.  In addition, after treatment patients had low circulating levels of Factor 
IX and some Factor IX protein infusion (Fabb and Dickson 2000; Kay et al. 2000).  There are 
many other diseases for which use of AAV-mediated gene delivery has led to phase I clinical 
trials, including muscular dystrophy (Wahl and Hesterlee 1999; Stedman et al. 2000), cancer 
(Ruan et al. 2001; Braun-Falco and Hallek 2001; Kanazawa et al. 2001), Gaucher disease (Wei 
et al. 1994), and arthritis (Robbins and Ghivizzani 1998; Cottard et al. 2000; Zhang et al. 2000).  
AAV has proven itself a premiere vector for gene delivery, although there are some drawbacks to 
its use.  AAV production is labor intensive, as it requires the purification of three separate 
plasmids for production.  As mentioned previously, the main limitation of AAV is its small 
packaging size; however, a number of different groups are working around this problem by using 
truncated proteins or smaller promoters (Chao et al. 1999, Gnatenko et al. 2000, Wang et al., 
2000).  Other groups are taking advantage of recombinant AAV’s ability to form large 
concatamers in vivo by delivering two viruses.  Each virus contains half of a gene and when co-
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 delivered form concatamers that are able to produce the full-length gene (Yang et al. 1999; Duan 
et al. 2000; Yan et al. 2000). 
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 1.6 AAV gene delivery to the δ-sarcoglycan deficient hamster 
The characterization of a sporadically occurring hamster model for δ-sarcoglycan 
deficiency serves to elevate the sarcoglycanopathies as a prime target for early work with gene 
delivery for muscular dystrophy.  The Bio 14.6 hamster is a well-characterized spontaneous loss-
of-function knockout for the δ-sarcoglycan gene (Nigro et al. 1997).  Adeno-associated virus 
(AAV) was the vector of choice for the treatment of this model, as all of the sarcoglycan genes, 
including δ-sarcoglycan, have relatively small cDNA’s (~2.0 kb each), and muscle has been 
observed as an easily transduced tissue using LacZ markers (Xiao et al. 1996; Greelish et al. 
1999; Li et al. 1999).  There are several reports of successful genetic, biochemical, histological 
and functional rescue of relatively large regions of the dystrophic muscle in this hamster model, 
both by us and others (Holt et al. 1998; Greelish et al. 1999; Li et al. 1999; Xiao et al. 2000).   
We described the first successful use of recombinant adeno-associated virus for the 
biochemical complementation of the hamster model (Li et al. 1999).  In this collaborative study, 
an AAV vector containing the complete human δ-sarcoglycan cDNA driven by a CMV promoter 
(AAV-CMV-δ-SG) was constructed and delivered to Bio 14.6 δ-sarcoglycan deficient hamster 
muscle by intramuscular injection.  Western blot analysis of muscle that was injected with the 
AAV-CMV-δ-SG and showed that there was a high level of δ-sarcoglycan production (Figure 4).  
Immunofluorescence analysis also showed extensive and efficient genetic and biochemical 
complementation of the primary defect in vivo (Figures 5, 6).     
 The injected Bio 14.6 hamster muscle was analyzed by immunofluorescence to confirm 
that the secondary biochemical defects were corrected by the rescue of the primary deficiency.  
Our results revealed that the secondary loss of the sarcoglycan complex was correctly restored to 
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 the membrane of the muscle tissue expressing the δ-sarcoglycan gene (Figures 5, 6).  
Interestingly, we also showed a range of expression levels of the δ-sarcoglycan gene in different 
myofibers.  Some produced enough to have proper localization to only the membranes of the 
myofibers, while other fibers were over-expressing the δ-sarcoglycan gene so that there was 
inappropriate cytoplasmic staining (Figure 5).  However, the over-expression of the δ-
sarcoglycan did not lead to formation of the complete sarcoglycan complex in the cytoplasm, as 
the other sarcoglycans (α-, β-, γ-) were only localized to the plasma membrane (Figure 6).  
Along with the restoration of the sarcoglycan complex, there was also a substantial improvement 
in the histology of treated muscles seen with hematoxylin and eosin (H&E) staining (Figure 7).  
In addition, there was no cytotoxic effect seen due to the expression or over-expression of the 
transgene, as evidenced by a lack of T-cell infiltration.  The transgene long-term expression and 
persistence of expression was followed and persisted for 4 months.  
We then went on to test whether the rescue of the primary biochemical defect (δ-
sarcoglycan) led to functional improvement of the muscle (Xiao et al. 2000).  The functional 
testing of muscle was performed in Dr. Jon Watchko’s laboratory.  It is important to note that 
there is an increased mass of muscle (hypertrophy) in the dystrophic Bio 14.6 hamster model 
when compared with the normal F1B hamster age-matched control.  This hypertrophic response 
is shared with most rodent models for the muscular dystrophies.  Specific tetanic force 
generation and specific twitch force is decreased in the Bio 14.6 relative to controls (Xiao et al. 
2000) (Figure 8).   
To determine if muscle functional measures were corrected by delivery of δ-sarcoglycan, 
in vitro contractile force measurements were performed on the tibialis anterior muscle (TA) of 
the Bio 14.6 hamster 4 months after treatment with a single injection of the AAV-CMV-δ-SG, 
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 untreated Bio 14.6 hamster, and normal F1B hamster.   The TA muscle was carefully removed 
from the legs of either the controls or the treated animals and subjected to in vitro 
electrophysiological stimulation and contractile measurement on a force transducer.  The treated 
muscle showed significant improvement in muscle mass, specific twitch, and specific tetanic 
force measurements, with a recovery of muscle strength of more than 97% in both specific twitch 
and tetanic force (Figure 8).  These results showed that treatment of dystrophic muscle using an 
AAV vector not only complemented the primary genetic and biochemical defects by restoration 
of the secondary biochemical defects and improvement in muscle histology, but it also restored 
muscle strength and size.    
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 1.6 Large scale gene delivery 
 One of the major hurdles facing gene delivery as a therapeutic approach for muscle 
disease is the need for large scale delivery and widespread rescue of muscle.  Muscle comprises 
~30% of body mass in humans, and introducing a delivery vehicle to all of the muscle groups in 
the body represents a daunting task.    One possible solution to this problem is taking advantage 
of muscle being a highly vascularized tissue, and therefore attempting systemic delivery of genes 
using the vascular system.  Some researchers have attempted this delivery method using AAV, 
but it appears that AAV vectors have substantial liver-tropism in vivo, with the majority of 
intravenously injected AAV vectors accumulating in liver and resulted in little to no expression 
in muscle (Ponnazhagan et al. 1997).  Many groups are working on bypassing the liver-tropism 
by discovery of receptor molecules that show greater tropism for muscle (Feero et al. 1997; 
Bouri et al. 1999).  However, this is a long-term approach that will require extensive 
characterization of potential ligands, and coupling to infectious virions.  Another alternative 
approach was recently published, where the authors showed that administration of AAV vector 
through the arterial supply of an isolated limb via an extra-corporeal membrane oxygenation 
(ECMO) circuit appears to yield widespread expression of the transgene in hamsters and in rats 
(Greelish et al. 1999).  Unfortunately, the exact nature of the ECMO procedure and its 
consequences has not been adequately studied, including the potential risks inherent in using 
histamine to induce endothelial permeabilization.  Indeed, our attempts to reproduce this difficult 
procedure led to lethality from histamine.  One final approach would be to perform multiple 
widespread intra-muscular injections.  However, this will require multiple accurate and 
consistent injections, and also raises another problem of the potentially inaccessible location of 
some muscle groups, such as the diaphragm.  
 26
 1.7 Conclusion of introduction 
 The sarcoglycanopathies represent a subgroup of the limb-girdle muscular dystrophies.  
Research on these diseases has characterized the genes and proteins of the four sarcoglycan (α, 
β, γ, and δ) whose deficiencies are responsible for these particular muscular dystrophies.  
Animal models of all sarcoglycanopathies have been made facilitating further characterization of 
the interaction of the sarcoglycan proteins and also permitting experimental therapeutics.   
 One of the treatment strategies that has been applied to the sarcoglycanopathies is gene 
delivery utilizing an adeno-associated virus (AAV).  AAV has been shown by several groups to 
be safe and effective for a wide variety of diseases, and more specifically has been shown to be a 
premiere vector for gene delivery to muscle.  AAV-mediated gene delivery of δ-sarcoglycan has 
been extensively studied by several groups.  The work presented in this dissertation serves to 
extend the understanding of gene delivery to the remaining sarcoglycans, and potentially provide 
additional insight into the interaction between the four sarcoglycan proteins.  In addition, we will 
gain a better understanding of some of the complicating factors involved with gene delivery to 
dystrophic muscle.   
 One complicating factor of gene delivery to disease muscle is the delivery to all of the 
muscle.  Other research groups have attempted to overcome this problem, with some limited 
success.  This dissertation presents a method for the transduction of large areas of muscle.   
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Figure 1. Schematic diagram of the dystrophin associated protein complex. 
This diagram represents the location and interaction of proteins at the myofiber membrane, 
including the sarcoglycan complex (Leiden Muscular Dystrophy web pages). 
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Figure 2. Comparison of human sarcoglycan proteins. 
A representative diagram of the human sarcoglycan proteins showing transmembrane domains 
(TM), phosphorylation sites (P), cysteine residues (SH), potential N-linked glycosylation sites 
(N), the N-terminal signal sequence (signal), and the ATP binding consensus sequence (ATP 
binding region).   
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Figure 3. Diagram of triple plasmid transfection method for production of AAV. 
AAV is currently produced in an adenovirus-free system using a triple plasmid transfection 
method.  The cis plasmid is the pAAV plasmid, which contains a promoter, the gene of interest, 
a splice site, and a polyadenylation signal, all flanked by two inverted terminal repeats (ITRs) 
that are the signaling sequences for packaging of AAV.  The trans AAV plasmid, p518, contains 
both the rep and cap genes from AAV to allow for replication and capsid protein production, but 
lacks any ITRs so that this sequence is not packaged and no wild-type AAV is produced.  The 
final plasmid is the adenovirus helper plasmid, pF∆6, which contains all of the necessary genes 
from the adenovirus genome to allow for AAV replication.  These three plasmids are co-
transfected into 293 cells, a human embryonic kidney cell line stably transduced with the 5’ end 
of the adenovirus genome.  The cells are subsequently harvested, and adenovirus-free replication 
deficient AAV containing the gene of interest can be purified. 
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Figure 4.  Western Blot analysis of in vivo δ-sarcoglycan production. 
Lane 1 is the wild-type positive control from the F1B hamster (Wt). Lane 2 is the untreated 
Bio14.6 hamster (Bio) showing an absence of δ-sarcoglycan.  Lanes 3-8 are Bio 14.6 hamster 
gastrocnemius muscle after injection with AAV-δ-sarcoglycan (Bio + AAV) (Xiao et al. 2000). 
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Figure 5. Over-expression of δ-sarcoglycan in the cytoplasm does not disrupt the correct 
localization of the sarcoglycan complex. 
(Panel A) AAV-δ-SG treated Bio 14.6 hamster muscle stained with antibody against the δ-
sarcoglycan protein.  (Panel B) Parallel section of the same treated Bio 14.6 hamster muscle 
stained with antibody against the α-sarcoglycan protein.  It is important to note that over-
expression of the δ-sarcoglycan led to cytoplasmic staining of some myofibers, but did not affect 
correct membrane localization of α-sarcoglycan (Xiao et al. 2000).  
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Figure 6.  Complete restoration of the sarcoglycan complex in treated Bio 14.6 hamsters. 
Top row consists of serial sections from a normal F1B hamster showing normal staining for the 
sarcoglycan complex.  Note that the antibody used against human δ-sarcoglycan does not cross 
react with hamster.  The middle row shows no staining of the sarcoglycans in the δ-sarcoglycan 
deficient hamster.  The bottom row shows restoration of all the sarcoglycans in AAV-δ-SG 
treated Bio 14.6 animals (Xiao et al. 2000). 
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Figure 7.  Histological examination of normal vs. rescued vs. dystrophic muscle. 
Panel A shows wild-type (WT) F1B hamster muscle with normal histology.  Note normal 
myofiber size with little variation in size, peripheral nuclei, and no fibrosis.  Panel B shows AAV 
δ-sarcoglycan rescued Bio 14.6 (Bio AAV) hamster muscle.  Panel C shows the untreated Bio 
14.6 (Bio) hamster muscle.  Note that the treated muscle (panel B) has restored myofiber size.  It 
also does not have the fibrosis seen in panel C.  However, they both have central nuclei, 
indicative of degeneration/regeneration, but we believe the reason for seeing it in the treated 
muscle is due to treatment after degeneration/regeneration has already occurred (Xiao et al. 
2000). 
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Figure 8. Functional recovery of Bio 14.6 hamster TA muscle with a single treatment. 
Bio 14.6 hamsters were injected at 40 days of age with an AAV δ-sarcoglycan containing vector 
and were studied at 4 months post-injection.  The Bio 14.6 hamster showed functional rescue of 
muscle following treatment with an AAV δ-sarcoglycan containing vector as evidenced by 
measurements of muscle mass, specific twitch force, and specific tetanic force which show 
restoration to 97% of normal muscle values.  Pt = twitch force, Po = tetanic force, N= newtons, 
CSA= cross sectional, *indicates a p<0.05 (ANOVA).  (F1B n = 8, Bio 14.6 untreated n = 9, Bio 
14.6 treated n = 4).   
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2.0 
 
Statement of the Problem 
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The biology of both normal and abnormal tissues is exceedingly complex, making 
controlled gene delivery with predictable outcomes a daunting task.  However, one gene delivery 
vector, recombinant adeno-associated virus (AAV), is particularly promising, especially in 
muscle where only a few attempts at gene delivery have led to a correction of biochemical, 
histological, and physiological symptoms of muscular dystrophy (Holt et al., 1998; Greelish et 
al., 1999; Li et al., 1999; Xiao et al., 2000). 
We hypothesized that biochemical complementation of animal models of muscular 
dystrophy could be accomplished by delivery of appropriate genes to muscle by AAV.  We 
predicted that different models and their corresponding genes would show differing levels of 
“success” (expression, persistence, and biochemical rescue), due to the intrinsic biochemistry of 
the muscle fiber and to variability in the interactions with the host immune system.  We felt that 
the study of closely related dystrophies and complementing genes would provide valuable insight 
into biochemical interactions within muscle. 
We employed murine and hamster models of muscular dystrophy to test the above 
hypotheses.  However, we also postulated that dystrophic muscle pathology itself has 
immunostimulatory properties that may elicit an immune response to delivered transgenes.  
Dystrophic muscle has many secondary consequences, occurring downstream as a result of the 
primary defect, that are shared between most muscular dystrophies; these downstream effects 
could act as immunostimulatory properties.  Some of these downstream effects, such as the 
degeneration/regeneration process and higher than normal amounts of macrophages, CD4, and 
CD8 T-cells (Arahata and Engel 1984; Arahata and Engel 1988), are referred to as hallmarks of 
muscular dystrophy.  Therefore, I tested the hypothesis that a transgene delivered to diseased 
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 muscle that does not correct the primary defect will result in generating an immune response to 
that transgene.     
Each of the sarcoglycan disorders provides an excellent model to isolate specific 
biochemical and pathological factors, which may mitigate the efficacy of gene delivery.  There is 
emerging biochemical and genetic data on each of the four sarcoglycan genes that allows careful 
comparison of the interaction of gene delivery with the biology of the system.  Gene mutations in 
any single sarcoglycan gene lead to a biochemical deficiency of all four sarcoglycan proteins.  
Thus, there is an intimate and mutually dependent (and stoichiometrically equal) interaction 
between these four protein products.  Considerable new data have shown a likely hierarchy in the 
assembly of the four sarcoglycan proteins during their transport through the golgi (Holt and 
Campbell 1998, Noguchi et al. 2000).  Also, the sarcoglycans have differing orientations through 
the membrane: three of the sarcoglycans have the carboxyl-terminus of the protein outside the 
plasma membrane, while one has the opposite orientation (Roberds et al. 1993a; Roberds et al. 
1994; Lim et al. 1995; Noguchi et al. 1995; Bonnemann et al.1996;  Jung et al. 1996; McNally et 
al. 1996; Nigro et al. 1996).  In addition, murine models for each sarcoglycan disease display 
similar muscular dystrophy phenotypes, including many of the hallmarks associated with the 
human disease (Duclos et al. 1998; Hack et al. 1998; Araishi et al. 1999; Coral-Vazquez et al. 
1999; Liu and Engvall 1999; Durbeej et al. 2000).    
 Another hurdle facing gene therapy for the treatment of muscle disease is the safe and 
efficient treatment of all muscles in a human patient.  This is a daunting task, as muscle consists 
of ~30% of the body’s mass, with many muscle groups not easily accessible by physical means.  
New methods of gene delivery must be developed before treatment of human muscle disease 
with gene therapy becomes a practical option.   
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Over-all hypothesis:  There are a series of complex variables, some disease specific, and some 
more generalized, which affect the efficacy of gene delivery. 
 
Hypothesis 1:  There are aspects of protein biochemistry that alter efficacy of gene therapy, even 
in closely related biochemical defects.  Altering biochemical interactions during protein 
assembly by over-expression of a transgene leads to cytotoxicity in some models, but not in 
others.  α-sarcoglycan gene delivery results in cytotoxicity of myofibers via improper assembly 
in the golgi, while delivery of β- or δ-sarcoglycan does not. 
 
Hypothesis 2:  There are aspects of tissue pathology that alter efficacy of gene therapy.  Muscle, 
which is functionally rescued shows little or no immunological reaction to AAV delivery of 
foreign protein, while dystrophic (non-rescued) muscle does show an immunological response 
against transgenes. 
 
Observation:  Development of a 10-needle injection manifold will allow for an accurate, 
reproducible, and safe method of gene delivery to large areas of muscle.   
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3.0 
 
α- and β-sarcoglycan gene delivery by AAV:  efficient rescue of muscle, but differential 
persistence of gene expression. 
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 3.1 Summary 
The sarcoglycanopathies are a group of four autosomal recessive limb-girdle muscular 
dystrophies (LGMD 2D, 2E, 2C, and 2F), caused by mutations of the α, β, γ, or δ sarcoglycan 
genes.  The δ-sarcoglycan deficient hamster has been the most utilized model for gene delivery 
to muscle by recombinant AAV vectors, although human patients with δ-sarcoglycan deficiency 
are exceedingly rare with only two patients described in the United States (Duggan et al., 
1997b).  Here I report construction and use of AAV vectors expressing α- or β-sarcoglycan, the 
genes responsible for the most common forms of the human sarcoglycanopathies.  Both vectors 
showed successful short-term genetic, biochemical, and histological rescue of both α- and β-
sarcoglycan deficient mouse muscle.  However, comparison of persistence of expression in 50 
injected mice showed substantial differences between AAV α-SG and β-SG vectors.  AAV β-SG 
showed long-term expression with no evidence of decrease 389 days after injection, while AAV 
α-SG showed a dramatic loss of positive fibers between 28 days and 41 days post-injection 
(p=0.006).  Loss of immuno-positive myofibers was correlated with significant inflammatory 
cell infiltrate, primarily macrophages.  To determine if the loss of α-sarcoglycan positive fibers 
was due to an immune response or to cytotoxic effects of α-sarcoglycan over-expression, Severe 
Compromised Immune-Deficient (SCID) mouse muscle was assayed for cytotoxicity after 
injection with AAV α-SG,  AAV β-SG, or PBS.  The results were consistent with over-
expression of α-sarcoglycan causing significant cytotoxicity.  The cytotoxicity of α-sarcoglycan, 
and not β- or δ-sarcoglycan over-expression, was consistent with biochemical studies of the 
hierarchical order of assembly of the sarcoglycan complex.  Our data suggests that even closely 
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 related proteins require different levels of expression to avoid toxicity and achieve long-term 
tissue rescue.  
3.2 Introduction 
Mutations in the genes encoding the dystrophin-associated sarcoglycan proteins (α, β, 
γ, and δ) are responsible for a subset of the genetically heterogeneous autosomal recessive 
muscular dystrophies (LGMD 2D, 2E, 2C, and 2F respectively) (Ozawa et al., 1998; Hoffman 
1999).  Patients with primary sarcoglycanopathies can be clinically similar to patients with 
primary dystrophin abnormalities (Duchenne and Becker muscular dystrophies) (Duggan et al., 
1997a; Ozawa et al., 1998).  Similarly, corresponding mouse models show similar phenotypes.  
Loss of function mutations in any one of the sarcoglycan genes (primary deficiency) leads to 
secondary deficiencies of the other sarcoglycan proteins (Jung et al., 1996a; Ozawa et al., 1998).  
The secondary loss of the sarcoglycans in both sarcoglycanopathies and dystrophinopathies 
occurs post-translationally (Chen et al., 2000), presumably due to inaccurate assembly and 
stabilization of the dystrophin/sarcoglycan/dystroglycan complex (Suzuki et al. 1992; Iwata et 
al. 1993; Roberds et al. 1993a; Suzuki et al. 1994; Ahn and Kunkel 1995; Jung et al. 1995; Yang 
et al. 1995; Rafael et al. 1996;  Vainzof et al. 1996; Sakamoto et al. 1997; Chan et al. 1998; 
Duclos et al. 1998; Ozawa et al. 1998; Araishi et al. 1999; Hack et al. 2000; Yoshida et al. 
2000).  Thus, there appears to be relatively stringent requirements for the macromolecular 
assembly of the sarcoglycans.  The primary sarcoglycanopathies are estimated to account for 
about 10-20% of cases with a Duchenne muscular dystrophy phenotype but normal dystrophin 
findings by muscle biopsy (Duggan et al., 1997a).  Here, “muscular dystrophy” refers to patients 
with primarily proximal weakness, persistent high serum creatine kinase levels, and no other 
associated symptoms.  Work completed in the Hoffman laboratory has shown the relative 
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 incidences of the different sarcoglycanopathies in an American/European population to be α > 
β >  γ  > δ  in about a 6:3:2:1 ratio (Duggan et al., 1997a).  
The sarcoglycanopathies have been a prime target for early work with gene therapy of 
muscle disease due to the small size of their genes (~1.5 kb) and the existence of the Bio 14.6 
hamster, a well characterized spontaneous loss-of-function knockout for the δ-sarcoglycan gene 
(Nigro et al., 1997).  This model, coupled with the emergence of recombinant AAV as a 
promising delivery vector for muscle, has led to a series of reports of genetic, biochemical, 
histological and functional rescue of relatively large regions of muscle in this hamster model 
from us and others (Holt et al., 1998; Greelish et al., 1999; Li et al., 1999; Xiao et al., 2000).  
AAV shows many advantages relative to other gene delivery systems for muscle.  The 
Hoffman laboratory has recently reported that muscle tissue appears to be the preferential site of 
infection and latency of wild-type AAV (Tezak et al., 2000).  In addition, the wild-type genome 
integrates preferentially into or close to troponin T gene (TNNT1) a highly muscle-specific gene 
on chromosome 19 (Dutheil et al., 2000).  Both in muscle and other tissues, AAV appears to be 
nonpathogenic with no known association with any disease (Gertz 1973), and AAV efficiently 
transduces cells with no reports of induction of a cellular immune response or cytotoxicity 
(Berns and Bohenzhy 1987; Flotte et al., 1993; Clark et al., 1997).  In contrast to all other 
(recombinant) viruses, AAV is also able to infect both mature and immature muscle (Li et al., 
1999).  The ability of AAV to infect muscle readily may be due to the high expression of AAV 
attachment receptors, heparin sulfate proteoglycan (HSP) in muscle (Summerford and Samulski 
1998;  Pruchnic et al. 2000; Cao et al. 2001).  Muscle also expresses an AAV co-receptor, 
integrin αVβ5 (Summerford et al. 1999; Pruchnic et al. 2000).  In addition, AAV is able to 
penetrate the basal lamina of muscle, while other viral vectors are not; this is possibly due to the 
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 AAV virion being only 20 nm in diameter, while adenovirus is 70-100 nm, and herpes is 120-
300 nm (Cao et al., 2001).  However, AAV's small size also limits the packaging capacity of the 
recombinant vectors to inserts of 3-5 kb.  This limitation makes it impossible to deliver the full-
length dystrophin gene, which could be used to treat the most common muscle disease, 
Duchenne muscular dystrophy.  Truncated dystrophin constructs encoding only the most critical 
regions of the dystrophin protein have recently shown functional rescue in mouse models (Wang 
et al., 2000).   
Two different groups have reported functional recovery in the δ-sarcoglycan deficient 
hamsters using AAV-mediated delivery of the normal human gene (Greelish et al., 1999; Xiao et 
al., 2000).  However, δ-sarcoglycan deficiency in humans is probably the most rare human 
muscle disease characterized to date, with only two unrelated patients reported in the United 
States by the Hoffman laboratory (Duggan et al., 1997b).  Murine knockouts for α-, β-, and γ-
sarcoglycan have recently been reported (Duclos et al. 1998; Hack et al., 1998; Araishi et al., 
1999; Liu and Engvall 1999; Durbeej et al. 2000), making new animal models available for 
testing gene delivery for the more common sarcoglycanopathies.  AAV gene delivery was 
recently reported in γ-sarcoglycan deficient animals using the human γ-sarcoglycan gene driven 
by a truncated muscle creatine kinase (MCK) promoter (Cordier et al., 2000).  This group 
reported intramuscular injection of 22 mice, with the majority of animals showing between 20-
40% biochemical rescue at 4-16 weeks post injection.  Prevention of histopathological changes 
in dystrophic muscle was reported if treated at early ages (< 3 weeks).  No immune 
complications or rejection of γ-sarcoglycan positive fibers in treated mice was described.  
Here I report construction of both α- and β-sarcoglycan AAV constructs and the use of 
these vectors in the corresponding knockout mice.  While both recombinant vectors showed 
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 widespread biochemical and immediate histological rescue of dystrophic muscle, only AAV β-
SG showed persistence of transgene expression.  I present data suggesting that the loss of α-
sarcoglycan expression was due to cytotoxicity from protein over-expression from the CMV 
promoter, likely as a result of incorrect assembly (dominant-negative effect) of the quaternary 
sarcoglycan complex.  These data suggest that expression levels of the protein from the 
transgene may be a critical variable in gene delivery efforts and, further, that even closely related 
biochemical defects may show very different cytotoxicity profiles.   
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 3.3 Materials and methods 
3.3.1 AAV vector production 
The complete coding sequences of both α- and β-sarcoglycan were amplified and cloned 
from primary human muscle biopsy cDNA.  α-sarcoglycan cDNA was amplified by using the 
following primer set: forward 5’ TCTGTCACTCACCGGGC 3’ and reverse 5’ 
GTGGACAGAGAAGGGAGGATGA 3’.  β-sarcoglycan cDNA was amplified using the 
following primer set: forward 5’ ACAGTCGGGCGGGGAGCT 3’ and reverse 5’ 
CATGTTGGTGACCTCTGGG 3’.  The amplified coding sequences were then cloned utilizing a 
TA cloning vector, pGem EZ cloning vector (Promega).  Each coding sequence was excised 
from the corresponding plasmid using NotI, and the fragments were gel purified and cloned into 
a cis-acting AAV vector (pAAV CMV α-SG or pAAV CMV β-SG).  This placed the gene under 
the CMV promoter, as we have previously described (Li et al., 1999).  Both constructs were 
subjected to automated sequencing of the portions internal to the AAV terminal repeats to verify 
integrity of the constructs.    
Recombinant AAV viral stocks were produced by the triple plasmid co-transfection 
method as previously described (Xiao et al., 1998).  Briefly, 1-2 hours prior to transfection, 293 
cells (human embryonic kidney cell line) at 70-80% confluence were given IMDM media.  
Freshly made 2.5M CaCl2 and HEBS buffer were combined with 12.5 µg cis-acting plasmid 
(pAAV CMV α-SG or pAAV CMV β-SG), 12.5 µg trans-acting plasmid (p518) (Xiao et al., 
1999), and 25 µg of adenovirus helper plasmid (pF∆6) (Xiao et al., 1999) and added to each 
150mm plate of 293 cells.  Media was replaced with DMEM the following day.  Media was 
collected, and virus was harvested 5 days post transfection.  AAV particles were purified through 
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 two sequential CsCl density gradients.  The particle number of each virus was determined using 
a slot-blot method.  Typical yields of virus were 2-5 x 1015 particles (2-5 x 1012 per mL).   
3.3.2 Mouse strains 
A murine gene knockout for α-sarcoglycan was obtained from Dr. Eva Engvall and was 
constructed as previously described (Liu and Engvall 1999).  The murine gene knockout for β-
sarcoglycan was obtained from Dr. Eijiro Ozawa and was constructed as previously described 
(Araishi et al., 1999).   Breeding colonies were established, and mice of specified ages were used 
for intramuscular injection of AAV. 
4-5 week old SCID (c3H/Smn.ClcrHsd-SCID) mice were obtained from Harlan.    
3.3.3 Intramuscular injections 
Mice deficient for either α- or β-sarcoglycan were injected with a recombinant AAV that 
would complement their deficiency (either AAV α-SG or AAV β-SG) in the tibialis anterior 
muscle.  Mice were injected either prior to the initial phase of degeneration/regeneration (under 2 
weeks of age), or during the later stable stage of histology after the initial round of 
degeneration/regeneration (~6 weeks of age) (Araishi et al., 1999; Liu and Engvall 1999).  Mice 
injected prior to degeneration/regeneration (< 2 weeks) received a single intramuscular injection 
of 10-15 µL (5 x 1010 viral particles).  Mice injected at older ages (> 6 weeks) received a single 
intramuscular injection of 35-40 µl (2 x 1011 viral particles).  Mice were sacrificed at  ~ 27, 41, 
133, or 388 days post injection. 
Seven week old SCID mice were injected in both tibialis anterior muscles with 20 µL of 
either PBS, AAV α-SG, or AAV β-SG (1 x 1011 viral particles per injection) and were sacrificed 
at 28 or 41 days post injection.    
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 A single intramuscular injection was given to each mouse, using a Hamilton 1702 syringe 
with a 22S gauge needle.  The needle was inserted longitudinally through the tibialis anterior 
muscle at the knee.  In mice older than one month the muscle was exposed by incision of the skin 
prior to injection, while younger mice were injected through the skin.   
3.3.4 Histological and immunofluorescent analyses  
Each tibialis anterior muscle was carefully dissected from both tendon insertion sites and 
directly flash frozen in liquid nitrogen-cooled isopentane.  Muscles were stored in hydrated, 
airtight containers at –80° prior to sectioning.  Cryosections were cut from the belly (center) of 
each muscle.  Hematoxylin and eosin staining was done on 8 µm frozen sections, while all 
immunostaining was done with 4 µm sections.   
For immunostaining, sections were thawed on Superfrost Plus slides (Fisher Scientific 
Inc.) then immediately incubated with 10% horse serum in PBS for 30 minutes.  The sections 
were incubated with primary antibody at room temperature for an hour.  The primary antibodies 
used were previously described, rabbit polyclonal anti-α-SG and anti-γ-SG antibody (Noguchi et 
al. 2000), rabbit anti-β-SG antibody (Araishi et al. 1999), rat anti-δ-SG antibody (Imamura et al. 
2000), and rabbit anti-sarcospan antibody (Noguchi et al. 1999).  Sections were washed 3 to 4 
times with the 10% horse serum in PBS and incubated with a Cy3-conjugated secondary 
antibody diluted in 10% horse serum and PBS for an hour, and subsequently washed an 
additional three times.  Sections were then mounted with Gel/Mount (Biomeda Corp.) and 
analyzed using a Nikon FXA microscope. 
3.3.5 Quantitation of transduced myofibers 
To determine the percentage of fibers that had been transduced by AAV, photomontages 
were produced from microscopic images of each entire TA cross-section immunostained with the 
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 appropriate anti-sarcoglycan antibody.  These montages were imported into NIH image v1.62, 
the area of the positive fibers was outlined and quantitated, and this value was divided by the 
total area of each TA.  On average, 30 cells represented approximately 1% of the muscle fibers 
(~3,000 fibers/TA).  Any muscles with less than 30 cells were reported as <1%.     
3.3.6 Characterization of immune responses 
Immune responses were characterized by both immunostaining, using antibodies directed 
against specific macrophage, T-cell, and B-cell markers, and by assay of circulating murine 
antibodies using an immunoblotting method.  For immunostaining 4 µm cryosections were 
incubated with the following antibodies:  anti-mouse CD4 (L3T4), anti-mouse CD8a (Ly-2), 
anti-mouse CD19 (1D3), and anti-mouse Mac-3  (all from PharMingen Inc).   
Immune cell infiltrate was measured in both injected and non-injected muscles.  
Quantitation was performed by immunofluorescently labeling both nuclei and specific immune 
cell infiltrate (B-cells, macrophages, CD4 and CD8 T-cells), taking random fields and counting 
the number of areas which were double stained, giving a specific cell count.   
Humoral immune responses were measured by western blotting of murine serum.  
Immunoblots were prepared using 100 µg total protein from human patient muscle biopsies from 
normal muscle, dystrophin deficiency  (Duchenne muscular dystrophy), and α-sarcoglycan 
deficiency (LGMD 2D).  The use of human biopsies for these studies was approved by the 
Children's National Medical Center IRB.  The protein samples were resolved on a 10% SDS 
PAGE gel along with a lane that contained AAV.  The primary antibody used was serum from 
injected or non-injected animals diluted 1:500.  The secondary antibody was an anti-mouse IgG 
conjugated to HRP (Amersham Pharmacia Biotech Inc.) diluted 1:1000.   An ECL (Amersham 
Pharmacia Biotech Inc.) western blot detection reagent was used to visualize immune complexes.    
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  3.3.7 Statistical analysis 
All statistical comparisons were done using either T-tests or analysis of variance 
(ANOVA).  Statistical significance of multiple comparisons was defined using Scheffe’s 
method.  All analyses were completed using Minitab V.13.1.   
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 3.4 Results 
3.4.1 Biochemical rescue of β-sarcoglycan deficient mouse by AAV gene transfer. 
The complete coding sequence of β-sarcoglycan was amplified and cloned from primary 
human muscle biopsy cDNA, placed under the control of a CMV promoter in AAV ITRs, and 
sequence-verified.  Recombinant AAV was produced by a triple plasmid transfection method 
(Xiao et al. 1998).   
 After β-sarcoglycan deficient knockout mice (Araishi et al., 1999) received a single 
intramuscular injection of AAV-CMV-β- sarcoglycan, all muscles examined showed extensive 
expression of human β-sarcoglycan (Figure 9).  Twenty-five (25) mice were analyzed at different 
time points (Table 1), with an average of 15% of the TA myofibers immunostaining positive for 
the transgene protein.  There was variability in expression, reflecting the different ages at which 
the mice were injected, and the difficulty in delivering precise amounts of virus by intramuscular 
injection.  Expression of the transgene was seen at all time points, including mice sacrificed at 
133 and 388 days post injection, where large areas of expression of β-sarcoglycan were still seen 
(Figure 10 and Table 1).   
 Mutations in the β-sarcoglycan gene lead to primary deficiency of β-sarcoglycan and 
secondary biochemical deficiencies of sarcospan, α-, γ-, and δ- sarcoglycans (Araishi et al., 
1999).  To test if the secondary biochemical defects were restored by AAV β-SG, serial sections 
were immunostained with antibodies for each protein (Figure 11).  All myofibers that were 
immuno-positive for β-sarcoglycan also demonstrated restoration of each secondary biochemical 
defect (Figure 11).  Thus, AAV delivery of β-sarcoglycan was able to restore all primary and 
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 secondary biochemical sarcoglycan deficiencies for long periods in β-sarcoglycan knockout 
muscle.       
3.4.2 Histological rescue of β-sarcoglycan deficient muscle with AAV expression of β-
sarcoglycan 
β-sarcoglycan deficient mice do not show evidence of myofiber degeneration or 
regeneration until about 2-4 weeks post partum (Araishi et al., 1999), similar to the other 
sarcoglycan deficient and dystrophin deficient mice (Hoffman and Kunkel 1989; Duclos et al., 
1998).  Myofibers that have not undergone any degeneration/regeneration show peripheral 
nuclei, while fibers that have undergone one or more cycles of degeneration/regeneration show 
central nuclei.  To determine if β-sarcoglycan delivery by AAV completely prevents myofiber 
degeneration, I injected mice at pre-necrotic stages (2 weeks old), then assayed for central nuclei 
in the post-necrotic stage.  TA muscle sections were stained with H&E and assayed for 
dystrophic pathology and quantitation of central nucleation.  β-sarcoglycan deficient mice that 
received AAV β-SG prior to the onset of degeneration/regeneration (2 weeks) showed complete 
histopathological rescue in muscle segments that expressed β-sarcoglycan, with all nuclei 
showing peripheral localization, and homogeneous fiber size in the rescued segments (Figures 9, 
10).  Muscle cells that receive β-sarcoglycan appear not to undergo degeneration/regeneration 
for over 388 days (Figure 10), which is in contrast to the β-sarcoglycan negative myofibers in the 
same section that show central nuclei and variable fiber size.  These results demonstrate that β-
sarcoglycan delivery by AAV rescues from lethality for over a year from injection.     
3.4.3 Initial rescue of α-sarcoglycan deficient muscle by an AAV vector, but lack of 
persistence     
α-sarcoglycan deficient animals were injected with an AAV α-SG and sacrificed at 
similar time points to those of the β-sarcoglycan deficient animals, as described in the methods 
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 portion of this chapter.  A total of 25 α-sarcoglycan deficient mice were injected and analyzed 
(Table 1).  Mice that were sacrificed at the early (28 day) time point showed substantial 
biochemical rescue (Figure 12) and showed restoration of all secondary biochemical defects 
(Figure 11).  However, histopathology was abnormal, with substantial immune cell infiltration 
(Figure 12).  In addition, mice injected at early ages (<2 weeks) showed central nucleation 
(Figure 16). By 41 days post injection, the majority of muscles studied showed < 5% α-
sarcoglycan positive myofibers (Table 1).  Biochemical recovery did not appear to be age 
dependent, as all animals regardless of age initially showed biochemical rescue, but also lost 
expression within 40 days.  Finally, all of the animals studied at 136 or 389 days post injection 
showed less than 1% of α-sarcoglycan positive fibers, with 3 of the 6 animals showing no 
positive fibers (Figure 17 and Table 1).   All injected animals were grouped as <30 days post-
injection, and >30 days post-injection, and the number of transduced fibers was compared for 
both α-sarcoglycan and β-sarcoglycan (Table 1, Figure 17, panel C). This analysis showed a 
highly statistically significant loss of α-sarcoglycan-positive myofibers after 30 days post-
injection (p=0.006), while there was no loss of β-sarcoglycan-positive myofibers (Figure 17, 
panel C).  
To characterize the immune cell infiltrate seen in muscles injected with AAV α-SG, 
muscles from control α- and β-sarcoglycan knockouts and muscle from AAV injected mice were 
stained for CD4 T-cell, CD8 T-cell, B-cell, and macrophage markers (Figure 12).  Uninjected α- 
and β-sarcoglycan deficient muscle showed only small foci of macrophage infiltration, with less 
T-cell (CD4, CD8) and no B-cell positive areas (data not shown).  β-sarcoglycan deficient 
muscle injected with AAV and studied 28 or 41 days post injection showed no inflammatory 
cells where biochemical rescue (α-sarcoglycan expression) was evident (H&E staining of Figure 
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 9, 10).  However, AAV α- SG injected muscle showed extensive macrophage infiltration (Figure 
12), while the contralateral leg showed relatively little infiltration (data not shown).  Some T-cell 
infiltration was also seen in the same areas that had macrophage infiltration; however, B-cells 
were rare (data not shown).  Simon Watkins’ laboratory performed quantitation of immune cell 
infiltrate; results indicated that AAV α- SG injected muscle has significantly more macrophages 
and CD4 positive T-cells than the non-injected legs (Figure 13, 14).   The lack of B-cell infiltrate 
suggested that over-expression of human α-sarcoglycan or β-sarcoglycan did not elicit a strong 
humoral response, consistent with previous studies of AAV in muscle (Jooss et al., 1998).   
To provide further evidence that the loss of α-sarcoglycan positive fibers was not 
associated with a humoral immune response, serum from injected mice was used for immunoblot 
analysis of circulating α- or β-sarcoglycan antibodies (Figure 15).  Total muscle protein from 
human patients with normal sarcoglycans, primary deficiency (α-sarcoglycan mutations), and 
secondary deficiencies (Duchenne and Becker muscular dystrophies) were stained with primary 
mouse sera at 1:500.  Sera from both AAV α-SG injected α-sarcoglycan deficient mice and 
AAV β- SG injected β-sarcoglycan deficient mice showed similar levels of antibodies to both the 
transgene and AAV coat proteins.  All AAV α- SG injected mice that showed a positive AAV 
response also had a positive α-sarcoglycan response, although not all animals that had an α-
sarcoglycan positive response were AAV positive.  All AAV β- SG injected mice that showed a 
positive β-sarcoglycan response had a positive AAV response, although not all β-sarcoglycan 
injected animals having a positive AAV response had a positive response to β-sarcoglycan 
(Figure 15).  This data suggested that a differential humoral response was not responsible for the 
different levels of persistence of AAV α-SG versus AAV β- SG.   
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 3.4.4 SCID mouse studies suggest increased cytotoxicity of α-sarcoglycan over-expression   
 To further address the issue of whether α-sarcoglycan over-expression caused an immune 
response or was cytotoxic, a cytotoxicity assay was carried out in SCID mice.  As these mice are 
positive for the sarcoglycans, have normal muscle, and lack both humoral and cellular immune 
responses, immune rejection of α-sarcoglycan positive fibers should not occur.  Thus, any 
observed loss of α-sarcoglycan positive fibers was likely due to cytotoxicity.  I assayed 
cytotoxicity by quantitation of central nucleation, which is highly reflective of the extent of 
myofiber degeneration/regeneration that is caused by direct injury from the needle track and/or 
cytotoxicity of the transgene.  Immune deficient SCID mice were injected in the TA muscles 
with either AAV α-SG, AAV β-SG, or PBS.  Histopathology was assayed at 28 and 41 days post 
injection.  The results showed that SCID mice injected with AAV α-SG had statistically higher 
number of central nuclei (p<0.001) than that of the PBS injected or the AAV β-SG injected 
animals, while numbers for the PBS injected and AAV β-SG injected animals were not 
statistically different (Figure 18).  This data suggests that over-expression of α-sarcoglycan is 
cytotoxic to myofibers, while β-sarcoglycan over-expression is not. 
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 3.5 Discussion 
Inherited deficiencies in either α- or β-sarcoglycan are responsible for two of the more 
common limb-girdle muscular dystrophies.  This report is the first to show construction and 
delivery of either α- or β-sarcoglycan using AAV.  Two previous reports described use of an 
adenovirus vector to deliver α-sarcoglycan (Duclos et al., 1998; Allamand et al. 2000).  Another 
report showed delivery of γ-sarcoglycan using an AAV MCK-γ-sarcoglycan construct and an 
adenovirus MCK-γ-sarcoglycan construct (Cordier et al., 2000).   A final report described the use 
of an adenovirus to deliver β-sarcoglycan (Durbeej et al. 2000).  All four reports showed 
biochemical rescue of the corresponding primary defect.  Histological rescue or persistence of 
expression was not studied in the β-sarcoglycan adenovirus report, while the γ-sarcoglycan 
adenovirus and AAV vectors showed expression to four months post injection and one of the α-
sarcoglycan adenovirus reports showed expression for seven months with histological correction.   
Here I document biochemical complementation of both α- and β-sarcoglycan deficient 
murine models using the corresponding AAV construct, including complete histological 
protection by AAV β-SG (Figure 9, 10, 11).  Our analysis of biochemistry, histology and 
persistence was based on 50 mice receiving a single intramuscular injection into a single large 
muscle group (tibialis anterior, TA), with normalization of all results to the entire cross-section 
of the center of each muscle.  In short-term experiments, both vectors were able to biochemically 
and histologically rescue up to 63% of myofibers in the TA muscle after a single intramuscular 
injection (Figure 9).  The extent of transduction was not dependent on the age of the mouse at the 
time of injection.  This is in contrast to herpes simplex virus and adenovirus vectors, where more 
efficient transduction is seen in neonatal animals (Feero et al., 1997).  Analysis of distribution of 
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 delivery through the TA muscle often showed extensive transduction relatively distant from the 
injection site, with positive fibers distributed at distances of up to 0.5 cm (Figure 9).   Relatively 
large volumes were injected (20 µl in 100 mg of muscle, representing a 20-30% increase in total 
volume), which may have facilitated delivery.   
Persistence of expression in injected mice was dramatically different between the AAV 
α-SG and β-SG vectors (Figure 17).  AAV β-SG showed long-term persistence of expression 
with no evidence of loss of positive myofibers through 388 days after injection.  In addition, β-
sarcoglycan delivery protected myofibers from cell death for over a year, as evidenced by 
peripheral nuclei in all transduced fibers (Figure 10).  To our knowledge, this is the first 
demonstration of complete histological rescue for over a year in any muscle disease gene therapy 
model.  The levels and persistence of β-sarcoglycan would be expected to be therapeutic in 
human muscle, if sufficiently large regions of muscle could be injected.  It is also pertinent to 
note that the CMV promoter was not inactivated in muscle; this is in contrast to liver, where loss 
of expression by promoter has been observed (Loser et al., 1998; Chen et al. 1999).   Finally, 
there was no evidence of cytotoxicity or immune response against β-sarcoglycan, despite the fact 
that the human protein was delivered to β-sarcoglycan knockout (null) mice.   
The observed efficacy using AAV β-SG was not seen when α-sarcoglycan was delivered 
using an identical CMV promoter construct and AAV backbone (Figure 17).  Delivery of α-
sarcoglycan by AAV showed successful short-term biochemical and histological rescue of 
muscle (Figure 12), with up to 63% of the entire TA showing strong α-sarcoglycan expression at 
28 days post injection.  However, in contrast to the β-sarcoglycan results, expression of α-
sarcoglycan was largely lost by 41 days post-injection (Figure 17, Table 1).  Loss of transduced 
myofibers was associated with extensive macrophage infiltration (Figure 12), and remaining α-
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 sarcoglycan positive fibers often showed dystrophic histopathology (central nuclei and variable 
diameter), suggesting that these fibers may have undergone cycles of degeneration and 
regeneration.  Indeed, the presence of central nuclei in α-sarcoglycan knockout mice injected at 
young, “pre-necrotic” ages suggests that these positive fibers may have originated from 
transduced myoblasts (satellite cells), as α-sarcoglycan positive fibers that contain central nuclei 
would have been regenerated from an α-sarcoglycan positive myoblast (Figure 12, 16).  We do 
not believe that this loss of α-sarcoglycan-positive fibers is due to difference in levels of over-
expression of AAV α-SG versus AAV β-SG, as the constructs are identical with regards to 
promoter, vector, and the virus was produced using identical methods.   
To investigate the mechanism of the loss of α-sarcoglycan transduced myofibers, 
immunodeficient mice (SCID) were injected with AAV α-SG, AAV β-SG or PBS (sham 
control).  I found evidence for cytotoxicity of the α-sarcoglycan expressing AAV (Figure 18), in 
that α-sarcoglycan positive fibers were lost even in the lack of an immune system.  Our SCID 
data was consistent with the relative absences of T- and B-cell infiltration seen in the immune 
competent knockout mouse model data, as cytotoxicity due to the over-expression of α-
sarcoglycan is not dependent on T- or B-cells, indicated by central nucleation in SCID mice and 
loss of positive fibers from the α-sarcoglycan deficient mice (Figure 12).   
In a recent report of over-expression of γ-sarcoglycan in transgenic mice, cytotoxicity 
was seen only if expression levels were 150 to 200-fold (36-57 gene copies) over their normal 
levels; over-expression at 5 times normal levels (3-4 copies) did not cause any cytotoxicity (Zhu 
et al., 2001).   These authors concluded that expression levels of γ-sarcoglycan are important for 
appropriate correction of the defect, similar to the conclusions that I have drawn here with 
regards to α-sarcoglycan.  While it is difficult to directly compare mRNA and protein levels 
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 from studies, current studies suggest that α-sarcoglycan over-expression is more cytotoxic than 
γ-sarcoglycan over-expression.  This is shown by comparing our results of over-expression of α-
sarcoglycan by AAV-mediated gene delivery being cytotoxic with the results from Zhu et al. 
(2001) of 5 times over-expression of γ-sarcoglycan in a transgenic mouse not causing any 
toxicity and the results from Cordier et al. (2000) showing the over-expression of γ-sarcoglycan 
by AAV-MCK-γ-SG mediated gene delivery also not having any toxic effects. 
Allamand et al. (2000) show that they can maintain expression of α-sarcoglycan at below 
normal levels, for seven months, using an adenovirus whereas I did not observe expression of α-
sarcoglycan for that amount of time (Allamand et al. 2000).  We believe that differences in 
persistence are due to one or a combination of differences in viral delivery methods, animal 
models, and/or the strength of the promoter driving the transgene.  First, there is the primary 
difference in their use of adenovirus and our use of AAV.  Second, different animal model 
knockouts were used.  Their animal knockout has disrupted exons 2 and 3 (Duclos et al., 1998), 
while the animal knockout that I use has disrupted exons 1 and 2 (Liu and Engvall 1999).  
However, both models do not produce any α-sarcoglycan protein products.  Finally, the most 
significant difference between our two results is most likely due to the use of different 
promoters.  They report the use of the rous sarcoma virus (RSV) promoter, which upon western 
blot analysis does not show over-expression.  In fact, according the data presented, when a 
muscle is transduced at ~90% there is at most ~50% normal levels of expression of the α-
sarcoglycan protein (Allamand et al. 2000).   I used the cytomegalovirus (CMV) promoter, 
which in an earlier collaborative study showed vast over-expression of δ-sarcoglycan both by 
western blot analysis and by immunofluorescence (Li et al. 1999).  CMV over-expression is seen 
in this study by cytoplasmic staining of α-sarcoglycan in muscle injected with AAV.  Our results 
 64
 taken with those of Allamand et al. results, have led us to propose some of the future studies that 
are discussed below.    
There are a number of possible explanations for the observed cytotoxicity of α-
sarcoglycan, and the lack of toxicity with the over-expression of the other three sarcoglycans 
(Figures 20, 21, and 22).  First, recent biochemical studies of the sarcoglycan complex have 
shown that the four protein transmembrane complex (α, β, γ, δ) is assembled in the golgi prior to 
transport to the cell surface (Noguchi et al., 2000).  This assembly has been found to be 
hierarchical, where β-sarcoglycan nucleates the complex, with subsequent addition of  γ- or δ-
sarcoglycan added in either order.  Finally the addition of α-sarcoglycan completes the tetramer 
(Noguchi et al., 2000) (Figure 19).  We hypothesize that over-expression of  α-sarcoglycan 
results in abnormal tetramers, with too many α-sarcoglycan subunits inappropriately filling the 
 γ- or δ- binding sites.  These βα2 or βα3 complexes may initially make it to the surface, but do 
not fulfill their normal function and/or accumulate in the golgi, and thereby lead to cytotoxicity 
(Figure 21).  Similarly, there is the potential that over-expression of α-sarcoglycan causes 
premature binding of α-sarcoglycan to β-sarcoglycan, which causes biochemical changes in the 
conformation of β-sarcoglycan so that it is unable to bind γ or δ-sarcoglycan.  This βα complex 
could in turn fail to transport to the cell surface, accumulate in the golgi, and again lead to 
cytotoxicity (Figure 22).   Indeed, I found some evidence of α-sarcoglycan-positive intracellular 
inclusions and cytoplasmic staining (see myofibers, top of Figure 10B), which were not seen 
with β-sarcoglycan.  It is important to state that both of these models allow for the possibility of 
low levels of proper assembly of the sarcoglycan subunits, which is seen with early rescue of the 
sarcoglycan complex (Figures 21, 22).  Therefore, the data suggests that accumulation of 
improperly formed complexes overtime leads to cytotoxicity.   
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 An additional possibility is that the human α-sarcoglycan protein is not sufficiently 
similar to the murine orthologue to functionally replace the protein in murine muscle.  The α-
sarcoglycan protein shows 89% identity between mouse and human, while the β-sarcoglycan 
protein shows 95% identity (Appendix A, B).  In addition, α-sarcoglycan is distinct from the 
other three sarcoglycans in that the N terminus is extracellular, while the other three have an 
intracellular N terminus (Figure 2).  The fact that I found short-term histological rescue of α-
sarcoglycan deficient muscle suggests the first mechanism, as a lack of function of human α-
sarcoglycan in murine muscle, would probably not result in time-dependent loss of transduced 
fibers.  In addition, our observation of cytotoxicity in SCID mice, which co-express murine α-
sarcoglycan, suggests that the human α-sarcoglycan has a dominant cytotoxic effect on 
transduced muscle, likely due to over-expression (i.e. co-expression of murine α-sarcoglycan 
was not protective).  Another potential reason for the cytotoxicity caused by over-expression of 
α-sarcoglycan is that α-sarcoglycan contains a particularly large cytoplasmic domain relative to 
the other three sarcoglycans, and this domain is presumably involved in protein-protein 
interactions at the cytoplasmic face of the plasma membrane.  Over-expression of α-sarcoglycan 
could lead to mislocalization or inappropriate binding of intracellular factors, to a greater degree 
than the other, smaller sarcoglycans.  Finally, a close relative of α-sarcoglycan, ε-sarcoglycan, is 
also expressed in skeletal muscle myofibers, and these two subunits are thought to be somewhat 
interchangeable in the sarcoglycan complex (with β, γ, and δ).  However, ε-sarcoglycan 
expression does not change in α-sarcoglycan-deficient mice, suggesting that ε-sarcoglycan 
cannot functionally rescue the sarcoglycan complex in myofibers (Liu and Engvall 1999).   
Nevertheless, it is possible that ε-sarcoglycan has some protective role in skeletal myofibers, and 
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 over-expression of α-sarcoglycan may exclude ε-sarcoglycan binding to the complex, thereby 
mediating toxicity via a dominant-negative effect on ε-sarcoglycan function. 
In conclusion, I show that delivery of two closely related proteins by AAV can lead to 
very different outcomes, with complete, long-term rescue of muscle by β-sarcoglycan, but 
significant cytotoxicity and muscle damage by α-sarcoglycan.  Studies are underway to 
determine if the use of the autologous α-sarcoglycan protein or gene promoter mitigate the 
cytotoxicity.  While our data suggests that human clinical trials using AAV over-expression of 
α-sarcoglycan may be premature, delivery of β-sarcoglycan is likely to provide a long-term 
therapeutic benefit.   
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Table 1. Summary of AAV α-SG and AAV β-SG injections to correspondingly deficient 
mice. 
 
Mouse # 
Amount of Virus/ 
Viral Particles 
Age 
Injected 
Days  
post- 
Injection 
Percentage 
of 
sarcoglycan 
positive 
fibers Mouse # 
Amount of Virus/ 
Viral Particles 
Age 
Injected
Days  
post -
Injection 
Percentage of 
sarcoglycan 
positive fibers
                    
Alpha sarcoglycan knockout mice    Beta sarcoglycan knockout mice    
Alpha # 1 40 µL/2x1011 50 28 29% Beta # 1 20 µL/1x1011 79 14 10% 
Alpha # 2 40 µL/2x1011 50 28 32% Beta # 2 20 µL/1x1011 79 14 8% 
Alpha # 3 40µL/2x1011 50 28 16% Beta # 3 39 µL//2x1011 91 26 14% 
Alpha # 4 40 µL/2x1011 50 28 24% Beta # 4 40 µL/2x1011 91 26 13% 
Alpha # 5 40 µL/2x1011 50 28 51% Beta # 5 80 µL/4x1011 133 26 12% 
Alpha # 6 40 µL/2x1011 50 28 25% Beta # 6 15µL/5x1010 18 27 13% 
Alpha # 7 15µL/5x1010 25 28 63% Beta # 7 15µL/5x1010 8 39 33% 
Alpha # 8 15µL/5x1010 25 28 28% Beta # 8 15µL/5x1010 15 40 53% 
Alpha # 9 15µL/5x1010 10 29 <1% Beta # 9 15µL/5x1010 15 40 17% 
Alpha # 10 15µL/5x1010 10 29 6% Beta # 10 15µL/5x1010 15 40 1% 
Alpha # 11 15µL/5x1010 10 29 2% Beta # 11 11 µL/5x1010 244 41 11% 
Alpha # 12 15µL/5x1010 15 41 26% Beta # 12 11 µL/5x1010 244 41 9% 
Alpha # 13 15µL/5x1010 15 41 14% Beta # 13 11 µL/5x1010 244 41 2% 
Alpha # 14 15µL/5x1010 15 41 4% Beta # 14 11 µL/5x1010 244 41 18% 
Alpha # 15 15µL/5x1010 15 41 4% Beta # 15 16.5 µL/5x1010 244 41 11% 
Alpha # 16 15µL/5x1010 25 41 4% Beta # 16 16.5 µL/5x1010 244 41 8% 
Alpha # 17 15µL/5x1010 25 41 8% Beta # 17 16.5 µL/5x1010 244 41 8% 
Alpha # 18 15µL/5x1010 10 41 0% Beta # 18 16.5 µL/5x1010 244 41 7% 
Alpha # 19 15µL/5x1010 10 41 0% Beta # 19 16.5 µL/5x1010 244 41 4% 
Alpha # 20 15µL/5x1010 15 135 0% Beta # 20 15µL/5x1010 8 133 54% 
Alpha # 21 15µL/5x1010 15 136 0% Beta # 21 15µL/5x1010 8 133 1% 
Alpha # 22 15µL/5x1010 15 136 <1% Beta # 22 15µL/5x1010 8 133 35% 
Alpha # 23 15µL/5x1010 15 136 1% Beta # 23 15µL/5x1010 8 133 5% 
Alpha # 24 15µL/5x1010 15 389 <1% Beta # 24 15µL/5x1010 8 260 <1% 
Alpha # 25 15µL/5x1010 15 389 0% Beta # 25 15µL/5x1010 8 388 16% 
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 Figure 9. Biochemical and histological rescue of β-sarcoglycan deficient mouse muscle after 
gene delivery of β-sarcoglycan by an AAV vector. 
Shown is a photomontage of the entire TA of a β-sarcoglycan deficient mouse after a single 
intra-muscular injection of AAV-CMV-β-SG (panels A, B).  Serial sections stained for 
histopathology (hematoxylin and eosin, panel A), and for restoration of the sarcoglycan complex 
(anti-α-sarcoglycan immunostaining, panel B) are shown from a TA injected at 15 days of age 
and sacrificed at 40 days post injection.  β-sarcoglycan deficient mouse muscle receiving the 
AAV β-sarcoglycan vector is rescued from the primary and secondary biochemical deficiencies 
and from myofiber degeneration, indicated by peripheral nuclei.  To compare the effect of age of 
the mice on delivery and transgene expression, 2 age groups (8 day old and 91 day old) were 
injected.  Mice injected at 8 days and sacrificed 39 days post injection show the same 
biochemical and histological rescue (panels C and D).  Mice injected at 91 days of age and 
studied 27 days post injection show biochemical rescue.  This older group of mice exhibited 
central nucleation due to the degeneration/regeneration process that occurred prior to AAV 
delivery (panels E and F).  This data shows that recovery of the biochemical defect is not 
affected by age at time of injection.  Note that the polyclonal antibody positively stains vascular 
smooth muscle of blood vessels, due to cross-reaction to unknown proteins.     
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 Figure 10. Long-term biochemical recovery and sustained cellular rescue of β-sarcoglycan 
deficient muscle after a single intra-muscular injection with AAV β-sarcoglycan. 
Shown is a photomontage of the entire TA muscle of a β-sarcoglycan deficient mouse after a 
single intra-muscular injection at 8 days of age, and studied 133 days after gene delivery (panel 
A, hematoxylin and eosin; panel B anti-α-sarcoglycan immunostaining).  Panel C and D showed 
serial sections of a β-sarcoglycan deficient mouse muscle after receiving a single intra-muscular 
injection at 8 days of age, and studied 388 days after gene delivery.  Both positive and negative 
regions are shown for comparison.  Protection of myofibers from degeneration/regeneration 
persists for over a year after delivery, as evidenced by the peripheral nuclei and homogeneous 
fiber size of the rescued fibers.  These findings indicate that AAV-mediated gene delivery of β-
sarcoglycan is able to confer long-term protection to myofibers from cellular lethality. 
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Figure 11. Restoration of all secondary biochemical defects in both α-sarcoglycan and β-
sarcoglycan deficient mice following gene delivery with the corresponding AAV. 
Shown are serial sections of an α-sarcoglycan deficient mouse TA that was injected at 25 days of 
age and studied 28 days post injection (top panels), and serial sections of a β-sarcoglycan 
deficient mouse TA that was injected at 15 days of age and studied at 40 days post injection 
(lower panels).  The sections were stained with hematoxylin and eosin and immunostained with 
antibodies against all four components of the sarcoglycan complex (α-SG, β-SG, γ-SG and δ-
SG), and sarcospan.  This data shows that AAV complementing the primary defect is also able to 
rescue all secondary biochemical defects.    
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Figure 12. Delivery of an α-sarcoglycan AAV vector leads to short-term biochemical rescue 
of α-sarcoglycan deficient mouse muscle associated with macrophage and T-cell 
infiltration. 
Shown are photomontages of the entire TA muscle of a mouse injected at 15 days of age with 
AAV α-sarcoglycan and sacrificed at 41 days post injection (panel A, hematoxylin and eosin; 
panel B anti-α-sarcoglycan immunostaining).  The H&E staining shows considerable cellular 
infiltrate that was not observed in contralateral, non-injected legs (data not shown).   To 
characterize the type of immune cell infiltrate, sections of the same treated muscle were stained 
for macrophages (anti-mac-3 antibodies, panel C), helper T-cells (anti-CD4, L3T4, antibodies, 
panel D) and cytotoxic T-cells (anti-CD8, Ly-2, antibodies, panel E).  Extensive macrophage 
infiltration is seen with both CD4 and CD8 T-cells.  B-cells were only rarely observed (not 
shown).  These findings suggest that elimination of α-sarcoglycan positive myofibers is not due 
to an IgG mediated immune response.  However an IgG immune response eliminating α-
sarcoglycan positive fibers cannot be completely ruled out in these experiments and is addressed 
in the SCID mouse experiments (see Figure 18). 
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Figure 13. Quantitation of macrophage infiltration. 
To determine the number of macrophages in the immune cell infiltrate of α-sarcoglycan deficient 
mice injected with AAV α-sarcoglycan, immunofluorescent double staining for both nuclei and 
macrophages was performed and quantitated.  Random fields were selected for quantitation, and 
8 injected muscles were compared with 4 non-injected muscles, to reveal that there are 
statistically more macrophages in the injected muscles than in the non-injected muscles.   
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Figure 14. Quantitation of CD4 positive T-cell infiltration. 
 
To determine the number of CD4 positive T-cells in the immune cell infiltrate of α-sarcoglycan 
deficient mice injected with AAV α-sarcoglycan, immunofluorescent double staining for both 
nuclei and CD4 positive T-cells was performed and quantitated.  Random fields were selected 
for quantitation and 8 injected muscles were compared with 4 non-injected muscles, to reveal 
that there are statistically more CD4 positive T-cells in the injected muscles than in the non-
injected muscles.   
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Figure 15. Western blot analysis of humoral immune response. 
Western blots were run using protein preparations from α-sarcoglycan deficiency (α-SG 
deficient), normal, and dystrophin deficiency (DMD) patient muscle or AAV.  The blots were 
probed using serum from injected or non-injected animals.  The total number of animals used for 
each group is as follows: 6 α-SG knockout (K/O) animals injected with AAV α-SG, 6 α-SG K/O 
non-injected animals, 6 β-SG K/O animals injected with AAV β-SG, 6 β-SG K/O non-injected 
animals.  Panel A shows positive bands from the western blot analysis (arrows indicate positive 
bands).  Animals were considered to have a positive antibody response to AAV if they exhibited 
an antibody response to at least 2 of the 3 coat proteins of AAV.  Panel B is a graphical 
representation of the results from all animals studied.  All AAV α-SG injected animals that 
exhibited a positive antibody response to AAV also had a positive response to α-sarcoglycan.  
All AAV β-SG injected animals that had a positive antibody response to β-sarcoglycan had a 
positive response to AAV.  The number of animals that exhibited an antibody response to their 
respective sarcoglycan was very similar with 4 AAV α-SG injected animal having a positive 
response and 3 AAV β-SG injected animals exhibiting a positive response.  Therefore, loss of 
expression in the AAV α-sarcoglycan injected animals does not appear to be correlated with a 
humoral immune response. 
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Figure 16. AAV CMV α-sarcoglycan biochemical rescue of α-sarcoglycan deficient mouse 
muscle is not age dependent. 
Shown are paired H&E and anti-α-sarcoglycan immunostaining from mice injected at 10 days 
old (panels A and B) or at 50 days old (panels C and D) and studied at 28 days post injection.  
Short-term biochemical rescue of the muscle is seen independent of the age of mice at the time 
of injection although expression is lost by 40 days post-injection (Table 1).  Immune cell 
infiltrate is seen at all times of delivery, often in areas that show rescued myofibers.  Arrows in 
panels A and B show an α-sarcoglycan positive fiber with a central nuclei.   
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 Figure 17.  α-sarcoglycan expression is not persistent. 
Shown is a region of the TA muscle of an α-sarcoglycan deficient mouse after injection with 
AAV CMV α-sarcoglycan at 15 days old, studied at 136 days post injection.  The 
immunofluorescent staining (panel A) for α-sarcoglycan is almost entirely absent at this time 
point, indicating loss of α-sarcoglycan expression over time.  In addition, this time point shows 
no sign of any histological rescue as indicated in the H&E staining (panel B).    
Panel C shows the mean percentage (± SE) of transduced fibers of both α-sarcoglycan deficient 
mice (Alpha) and β-sarcoglycan deficient mice (Beta), studied at either < 30 days post injection 
(< 30 days post) or > 30 days post injection (> 30 days post) (see Table 1).   Injected α-
sarcoglycan deficient mice studied at > 30 days post injection show a highly statistically 
significant loss of transduced fibers, whereas β-sarcoglycan injected mice show no loss of 
transduced fibers (NS = not significant).     
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Figure 18. SCID mice injected with either AAV α-sarcoglycan, AAV β-sarcoglycan or PBS 
show that over-expression of α-sarcoglycan is cytotoxic. 
Shown are TA muscles from SCID mice stained with hematoxylin and eosin after injection with 
AAV α-sarcoglycan (panel A) or AAV β-sarcoglycan (panel B).  Both mice were injected at ~ 
48 days of age and studied ~ 43 days after injection.  AAV α-sarcoglycan injected muscle shows 
widespread central nucleation of myofibers, indicating cell death and regeneration (panel A).  
AAV β-sarcoglycan injected muscle shows fewer centrally nucleated myofibers, occurring along 
the needle track (panel B).  Panel C is a graphical representation of the number of central nuclei 
in the TA of SCID mice that were injected with either AAV α-sarcoglycan, AAV β-sarcoglycan 
or PBS.  The number of central nuclei (a measurement of cytotoxicity in normal muscle) are 
statistically significantly greater (*) in SCID mice injected with AAV α-sarcoglycan than in 
SCID mice injected with either AAV β-sarcoglycan or PBS (p<0.001).  However, AAV β-
sarcoglycan and PBS injected muscles are not statistically different from one another.    This data 
suggests that over-expression of α-sarcoglycan is cytotoxic to myofibers. 
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Figure 19. Model for biochemical assembly of the sarcoglycan complex. 
In the model based on work by Noguchi et al. (2000) diagrammed above, β-sarcoglycan 
nucleates the sarcoglycan complex, followed by addition of either γ-sarcoglycan or δ- 
sarcoglycan without apparent preference between the two subunits.  Next γ-sarcoglycan binds to 
the complexes that already have δ-sarcoglycan and δ-sarcoglycan binds to complexes that 
already have γ-sarcoglycan.  The complex formation is complete with the addition of α-
sarcoglycan.  (β= β-sarcoglycan, δ = δ-sarcoglycan, γ = γ-sarcoglycan, and α = α-sarcoglycan) 
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Figure 20. Over-expression of β-, γ-, δ-sarcoglycan should not affect the formation of the 
sarcoglycan complex.   
Over-expression of β-sarcoglycan should not affect the formation of the complex, since it 
nucleates the complex, and the rate limiting step would be the addition of δ- or γ-sarcoglycan.  
Over-expression of δ- or γ-sarcoglycan will drive the second addition to the complex toward the 
over expressed protein, but should not affect formation of the complex, since either protein can 
be added second in the complex formation.  (β= β-sarcoglycan, δ = δ-sarcoglycan, γ = γ-
sarcoglycan, and α = α-sarcoglycan) 
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Figure 21. Potential model for over-expression of α-sarcoglycan causing cytotoxicity by 
improper binding of α-sarcoglycan to β-sarcoglycan. 
A potential mechanism for over-expression of α-sarcoglycan causing cytotoxicity is the 
improper binding of α-sarcoglycan to β-sarcoglycan in the binding positions for either γ- or δ-
sarcoglycan.  The production of incorrect complex will accumulate over time and will lead to 
cytotoxicity.  It is important to note that due to random association of complex subunits, some 
correct sarcoglycan complex will be formed, which will account for the initial rescue seen in the 
α-sarcoglycan deficient mice treated with an AAV α-sarcoglycan.  (β = β-sarcoglycan, δ = δ-
sarcoglycan, γ = γ-sarcoglycan, and α = α-sarcoglycan) 
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Figure 22. Potential model for over-expression of α-sarcoglycan causing cytotoxicity by 
incorrect order of assembly of the sarcoglycan complex. 
Another potential mechanism for over-expression of α-sarcoglycan causing cytotoxicity is the 
incorrect order of assembly of the complex with the addition of α-sarcoglycan occurring first or 
second in the complex formation, which may biochemically change the conformation of β-
sarcoglycan and prevent the attachment of γ- or δ-sarcoglycan to complete the complex 
formation.  The production of incorrect complex will accumulate over time and will lead to 
cytotoxicity.  It is important to note that due to random association of complex subunits, some 
correct sarcoglycan complex will be formed, which will account for the initial rescue seen in the 
α-sarcoglycan deficient mice treated with an AAV α-sarcoglycan.  (β= β-sarcoglycan, δ = δ-
sarcoglycan, γ = γ-sarcoglycan, and α = α-sarcoglycan) 
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4.0 
 
Immunostimulatory properties of dystrophic muscle alter persistence of transgenes 
delivered by adeno-associated viral vectors. 
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 4.1 Summary 
 Inherited biochemical defects in patients with muscular dystrophy result in cycles of 
degeneration and regeneration in muscle.  Complementation of the biochemical defects has been 
the major focus of experimental gene delivery in animal models of dystrophin and sarcoglycan 
deficiency.  We hypothesized that the degeneration/regeneration cycles and immune cell 
infiltrate in dystrophic muscle would cause an immunostimulatory response, leading to increased 
immune response to a transgene, whereas histologically normal muscle would not.  To test this 
hypothesis, I delivered both marker and therapeutic genes to dystrophic muscle and to normal 
muscle using a recombinant adeno-associated virus (AAV).  I show that dystrophic muscle does 
indeed elicit a substantially greater immune response to β-galactosidase, compared to normal 
muscle.  I also show that biochemical rescue of the dystrophic myofibers could mitigate the 
immunostimulatory properties of dystrophic muscle by co-delivery of a therapeutic transgene (β-
sarcoglycan) and the marker transgene (LacZ).   Our results suggest that full biochemical and 
histological rescue of dystrophic muscle must be accomplished to avoid strong immune 
responses against delivered transgenes.  
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 4.2 Introduction 
 Gene delivery using either adeno-associated viral vectors or adenoviral vectors has 
shown promise in biochemical rescue in animal model of different types of dystrophies.  Adeno-
associated virus has garnered the most attention due to the apparent lack of an aggressive 
immune response against the transgene in muscle, and hence, impressive persistence and high 
level of expression in AAV transduced myofibers (Duclos et al. 1998; Holt et al. 1998; Greelish 
et al. 1999; Li et al. 1999; Xiao et al. 2000; Cordier et al. 2000; Durbeej et al 2000; Wang et al. 
2000).  We hypothesized that this success of AAV is dependent on the avoidance of losing the 
transgene from either degeneration of the transduced myofiber or the induction of an immune 
response to the transgene by the dystrophic muscle.  The degeneration/regeneration process in 
dystrophic muscle has been shown to lead to substantial levels of cellular infiltrate, including 
high amounts of macrophages, CD4 and CD8 T-cells, with lower amounts of B-cells and natural 
killer/killer cells (Arahata and Engel 1984; Arahata and Engel 1988).  We believe that the 
degeneration/regeneration process itself may be immunostimulatory.  The degeneration of a 
myofiber will lead to the presence of immune cell infiltrate.  The degeneration will also release 
the cellular contents of the myofiber, including any “foreign” transgene product, into the 
extracellular space.  Because the cellular contents of the myofiber include the foreign transgene 
product, clearance of it by the immune cells could lead to the immune-dependent clearance of 
other non-degenerating myofibers that are producing the transgene protein.  To date, AAV-
mediated marker gene transfer studies resulted in high levels of transgene expression in normal 
muscle, yet no parallel studies have demonstrated success in dystrophic muscle.  This issue is 
important to resolve, as gene delivery efforts in Duchenne muscular dystrophy 
(dystrophinopathies) have been recently focused on the construction of dystrophin mini-genes 
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 that can be contained within the size-constrained AAV backbone  (Wang et al. 2000).  These 
truncated dystrophin proteins are known, from human patients studies, to only partially rescue 
the biochemical defect (Hoffman et al. 1988; Hoffman et al. 1989).  While biochemically and 
histologically rescued myofibers using a normal protein delivered by AAV would not be 
expected to elicit any immune response against the transgene, a myofiber rescued with a 
truncated semi-functional protein might retain some dystrophic characteristics and the muscle 
would still be immunostimulatory.   
 A recent report showed impressive long-term rescue of dystrophin deficient (mdx) mice 
with a dystrophin mini-gene (Wang et al. 2000).  This report showed that partial biochemical 
rescue using a highly truncated form of dystrophin had long-term persistence, with no obvious 
immune response.  One reason why gene transfer studies by Wang et al. (2000) did not elicit an 
immune response with the semi-functional dystrophin may be that murine muscle is more 
“tolerant” of dystrophin abnormalities than higher vertebrates (dog and human).  The higher 
vertebrates show constant degeneration/regeneration, while mdx muscle functionally recovers to 
some extent (Bulfield et al. 1984; Sicinski et al. 1989; Partridge 1991; Infante and Huszagh 
1999; Hoffman 2001).  Thus, the same highly truncated dystrophin construct might be less 
protective against dystrophic features of muscle in humans than in mice and, therefore, could 
elicit an immune response in humans.    
We believe that dystrophic muscle may contain immunostimulatory factors, due to 
muscle fiber degeneration/regeneration.  The resulting immune cell infiltrate, may act to boost 
the immune response to delivered transgenes if the transgenes do not fully rescue the primary 
biochemical defect.  To test if there are immunostimulatory properties of dystrophic muscle, we 
used a dystrophic mouse model.  Here, we use delivery of marker genes and therapeutic genes by 
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 AAV, both singly and together, in both normal and dystrophic muscle.  Important to the 
interpretation of these results is the finding that co-injected AAV vectors form concatamers, thus 
co-infecting the same cells (Yang et al. 1999; Duan et al. 2000; Yan et al. 2000).  We show that 
dystrophic muscle does indeed elicit a dramatic immune response against a marker gene protein, 
and that this response is attenuated by biochemical rescue of the myofibers by a therapeutic 
transgene.    
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 4.3 Materials and methods 
4.3.1 Virus production  
Construction of AAV vectors containing LacZ was previously described (Li et al. 1999).  
The construction of an AAV containing the human β-sarcoglycan cDNA driven by the CMV 
promoter was completed as follows.  The human β-sarcoglycan cDNA was amplified using the 
following primer set: forward 5’ ACAGTCGGGCGGGGAGCT 3’ and reverse 5’ 
CATGTTGGTGACCTCTGGG 3’.  AAV was produced using a triple plasmid co-transfection 
method previously described (Xiao et al. 1998).  Viral titers were determined by DNA dot-blot 
analysis and found to be in a range of 2-5 x 1012 particles per mL. 
4.3.2 Mouse strains and delivery of virus 
β-sarcoglycan gene knockout mice were obtained from Dr. Eijiro Ozawa, and were 
previously described (Araishi et al. 1999).   Breeding colonies of these animals were established, 
and mice at 108 days old were used for intramuscular injection of AAV.  Normal C57BL/6NHsd 
mice were obtained from Harlan, and were injected at 90 days old.   
Each mouse received a single intramuscular injection into the tibialis anterior (TA) 
muscle.  Those mice receiving only one virus received an injection containing 11 µL of AAV 
LacZ (5 x 1010 viral particles) and 11 µL of PBS for a total of 22 µL.  Those receiving two 
viruses received a single injection containing 11 µL of AAV LacZ (5 x 1010 viral particles) and 
11 µL of AAV β-sarcoglycan (5 x 1010 viral particles) for a total of 22 µL (1 x 1011 viral 
particles).  All mice were sacrificed at 43 days post injection. 
4.3.3 β-galactosidase and immunofluorescent analysis 
Each tibialis anterior (TA) muscle was carefully dissected from both tendon insertion 
sites and immediately flash frozen in liquid nitrogen-cooled isopentane.  Muscles were stored in 
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 hydrated, airtight containers at –80° prior to sectioning.  β-galactosidase staining was done on 8 
µm frozen sections, while all immunostaining was done on 4 µm frozen sections.   
β-galactosidase staining was performed on fresh sections, which were immediately fixed 
using 0.5% gluteraldehyde for 10 min.  Slides were then rinsed 3 times for 10 minutes with PBS, 
and stained with the X-gal Staining Set (Roche Molecular Biochemicals) overnight.  Finally, 
slides were rinsed with PBS and mounted with Gel/Mount (Biomeda Corp.).  Once the staining 
was completed, the number of cells producing β-galactosidase in the entire TA muscle (cross-
section at belly [center of muscle]) was counted under 10X magnification (Nikon FXA 
microscope). 
For immunostaining, sections were thawed on Superfrost Plus slides (Fisher Scientific 
Inc.) then immediately incubated with 10% horse serum in PBS for 30 minutes.  The sections 
were incubated with primary antibody at room temperature for an hour.  The primary antibody 
used was a rabbit anti-β-SG antibody previously described (Araishi et al. 1999).  Sections were 
washed 3 to 4 times with 10% horse serum in PBS and incubated with a Cy3-conjugated 
secondary antibody diluted in 10% horse serum and PBS for an hour, and subsequently washed 
an additional three times.  Sections were then mounted with Gel/Mount (Biomeda Corp.) and 
analyzed using a Nikon FXA microscope. 
4.3.4 ELISA assay 
ELISA assays were done by first adding 50 µL of purified β-galactosidase from E. coli 
(Sigma) at 0.4mg/mL in Carbonate/Bicarbonate buffer pH 9. 6 (Pierce Chemical Company), to 
each well of a 96 well assay plate for 2 hours at room temp.  Plates were washed, and 200 µL of 
Superblocker PBS (Pierce Chemical Company) was added to each well and incubated for 30 
minutes at room temp.  Each well was then rinsed with 3 x 100 µL of wash buffer (0.05% of 
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 Surfact-Amps Tween 20 (Pierce Chemical Company) diluted in Superblocker PBS).  Each 
ELISA plate was freshly made for each experiment.   
Assays for antibodies to β-galactosidase in mouse serum were done by first collecting 
serum from whole blood collected at 43 days post-injection from AAV injected mice.  Serum 
was first diluted 1:1 with PBS and 0.1% BSA and added to the first well of the ELISA plate.  
Those samples that were initially determined to have a higher antibody titer serum were diluted 
at 1:20 for each of the 8 remaining wells, while those with lower antibody titer serum were 
diluted at 1:5 over a total of 8 wells.   Diluted serum was incubated on the plates for 1 hour at 
room temperature, then washed three times.  Diluted secondary antibody (anti-mouse HRP 
1:6000) was added for 1 hour, and washed.  100 µl of TMB substrate solution (Pierce Chemical 
Company) was added to each well and incubated for approximately 20 minutes.  The reaction 
was stopped by adding 100 µl of 2 M H2SO4 to each well.  Absorbance was read using a Thermo 
Max plate reader (Molecular Devices Corp.) at 450 nm, and the data was analyzed using Soft 
Max Pro version 2.6.1 (Molecular Devices Corp.).   
4.3.5 Statistical analysis 
 Data was determined to be parametric; therefore all statistical comparisons were 
performed using Student’s t-tests.  Statistical analysis of the ELISA data was performed at an 
absorbance reading of 1, where values for each sample were determined by interpolation from 
the absorbance curve (Figures 25, 26).  In this data, one data point was omitted from the analysis 
after further examination (i.e. linear regression of absorbance in response to serum dilution and 
subsequent calculation of Cook’s distance) defined it as a statistical outlier.   
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 4.4 Results  
4.4.1 AAV gene transfer of LacZ, or LacZ and β-sarcoglycan to both normal and β-
sarcoglycan deficient mice 
Recombinant AAV containing either the LacZ gene (Goodman et al. 1994), or the cDNA 
for β-sarcoglycan (Dressman et al. submitted) was produced by a triple plasmid transfection 
method (Xiao et al. 1998).  Both transgenes were driven by a CMV promoter and were flanked 
by AAV ITRs.  Each construct was verified by DNA sequencing.    
Normal mice and β-sarcoglycan deficient mice received either an injection of AAV LacZ 
alone or a combination of AAV LacZ and AAV β-sarcoglycan.  Five β-sarcoglycan deficient 
mice and 3 normal mice received a single intramuscular injection into the TA containing an 
equal mix of both AAV LacZ and PBS.  Five β-sarcoglycan deficient mice and 4 normal mice 
received a single intramuscular injection into the TA containing an equal mix of AAV LacZ and 
AAV β-sarcoglycan. 
Mice were sacrificed 43 days post-injection, and each TA muscle was analyzed for β-
galactosidase positive myofibers.  A comparison between the normal and β-sarcoglycan deficient 
mice receiving the AAV LacZ virus alone showed a statistically significant difference (p<0.05) 
between the number of β-galactosidase producing myofibers, with the β-sarcoglycan deficient 
mice having many fewer β-galactosidase positive myofibers.  The mean number of β-
galactosidase positive myofibers in the β-sarcoglycan deficient mice was 14 ± 24 (SEM), while 
the normal mice had a mean of 282 ± 157 myofibers (Figure 23).   
The comparison between normal mice and β-sarcoglycan deficient mice that received the 
mixture of both AAV LacZ and AAV β-sarcoglycan showed no statistically significant 
difference in the number of β-galactosidase positive myofibers.  The mean number of β-
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 galactosidase producing cells in the β-sarcoglycan deficient mice receiving both viruses was 167 
± 202 myofibers, and the mean number of myofibers for the normal mice receiving both viruses 
was 63.5 ± 42.8 (Figure 23).   
To confirm that there was co-transduction of myofibers by the two viruses, β-sarcoglycan 
deficient muscle that received both viruses was sectioned and double-stained for both β-
galactosidase and for β-sarcoglycan production.  Analysis of this muscle confirmed that the 
majority of myofibers were positive for both β-galactosidase and β-sarcoglycan (Figure 24).     
4.4.2 ELISA analysis of serum antibody titers against β-galactosidase   
To assay antibody production against β-galactosidase, serum from each injected mouse 
was analyzed by ELISA.  Serum dilutions were plotted in a log-linear dilution curve for each of 
the β-sarcoglycan deficient animals (Figure 25) and without outliers (Figure 26).  All normal 
animals injected with either AAV LacZ virus alone or both AAV LacZ and AAV β-sarcoglycan 
showed no detectable serum antibodies to β-galactosidase (Figure 25 and data not shown).   
β-sarcoglycan deficient mice showed considerably more serum antibodies to β-
galactosidase (Figure 25), with the highest titers in animals receiving the AAV LacZ alone.  Co-
transduction of AAV LacZ and AAV β-sarcoglycan showed attenuation of the immune response 
against β-galactosidase (Figures 23, 26), suggesting that biochemical rescue of myofibers from 
the dystrophic phenotype could, in part, mitigate the immunostimulatory effect of dystrophic 
muscle.   
To determine the antibody titer differences between β-sarcoglycan deficient animals 
receiving AAV LacZ virus alone or both AAV LacZ and AAV β-sarcoglycan, the dilution value 
of animal’s serum was interpolated at an absorbance value of 1.  When these interpolated 
dilution values, minus one outlier as described below, were compared, the mean dilution value of 
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 the β-sarcoglycan deficient animals receiving AAV LacZ virus only was significantly higher 
(p=0.010) than the mean dilution value of the group receiving both AAV LacZ and AAV β-
sarcoglycan (Figure 26).   
One β-sarcoglycan deficient animal that received both AAV LacZ and AAV β-
sarcoglycan showed a noticeably higher serum dilution value at an absorbance of 1 than the other 
4 mice receiving both viruses.  This value was further examined and determined to be a 
statistical outlier.  A simple linear regression was performed with serum dilution as the 
dependent variable and injection group as the categorical independent variable.  From this 
regression line, a Cook’s distance, which measures the influence of an observation on the 
regression equation, was calculated for each observation.  Observations with a Cook’s distance 
greater than 4/n can be considered suspect and unduly influencing the equation estimation.  
(Kleinbaum et al. 1998; StataCorp. 2001).  One data point was found to have an increased 
Cook’s distance, and therefore was omitted from the analysis.  Comparison between the β-
sarcoglycan deficient mice receiving both AAV LacZ and AAV β-sarcoglycan and mice 
receiving AAV LacZ alone using all animals exhibited only partial significance (p=0.0545), with 
mice receiving only one virus having a higher mean serum dilution than those receiving two 
viruses.  This change in significance level from 0.0545 to 0.010 by removing one data point 
further shows that point’s undue influence on the statistics.      
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 4.5 Discussion 
Experimental gene delivery research has generally focused on either marker gene studies 
in normal tissues, or delivery of therapeutic genes to abnormal tissue.  Given the pathological 
nature of many diseased tissues, such as dystrophic muscle, it is likely that the abnormal state of 
the muscle could lead to an exacerbation of immune responses to transgenes.  True biochemical 
and histological rescue of cells by a therapeutic transgene might mitigate the potential 
immunostimulatory effect of dystrophic muscle.  We felt that it was important to begin to 
address this possibility, given that increasing attention is being placed on the use of modified 
therapeutic genes in muscular dystrophy research.  One example is the use of highly truncated 
dystrophin proteins, which are deliverable by the size-limited AAV vectors and are able to retain 
some of the biological functions needed to rescue muscle histologically and functionally.  It is 
possible that these semi-functional therapeutic proteins will not completely rescue the dystrophic 
phenotype, and thus have potential for eliciting an increased immune response against the 
transgene. 
To test this, I carried out a series of experiments in vivo, using both a marker gene 
delivered by AAV (LacZ), and a therapeutic gene (β-sarcoglycan) to both normal mouse muscle, 
and dystrophic mouse muscle (β-sarcoglycan deficient).  I found that normal mice did not elicit 
detectable immune responses against the marker transgene, despite the high expression level in 
muscle, the potential high antigenic nature of this bacterial-derived protein, and co-injection and 
expression of human β-sarcoglycan vector.  This data is consistent with previously published 
reports showing high levels of expression of novel transgenes in normal mouse and rat muscle, 
with no detectable immune response, and consequent long-term persistence of the transduced 
myofibers (Xiao et al. 1996; Snyder et al. 1997; Li et al. 1999).   
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 In contrast, parallel studies of dystrophic muscle (β-sarcoglycan deficient) showed an 
aggressive immune response against the marker gene (Figures 25, 26), as evidenced by high 
serum titers to purified β-galactosidase.  This data shows that the milieu of the dystrophic 
muscle, due to infiltration of macrophages and T cells, or due to increased antigen presentation 
of the biochemically abnormal myofibers, or both, is conducive to development of immune 
responses against the transgene.  In this respect, the dystrophic muscle appears to have an 
immunostimulatory effect. 
We and others have shown that biochemical rescue of dystrophic muscle leads to long-
term persistence of therapeutic transgenes delivered by AAV, with little or no evidence of 
inflammatory cell infiltrate (Duclos et al. 1998; Holt et al. 1998; Greelish et al. 1999; Li et al. 
1999; Xiao et al. 2000; Cordier et al. 2000; Durbeej et al 2000; Wang et al. 2000; Dressman et 
al. submitted).  This suggests that dystrophic muscle that has been biochemically and 
histologically rescued may no longer have immunostimulatory properties.  To test this 
hypothesis, I co-injected both marker and therapeutic AAV into dystrophic muscle, with the goal 
of showing that the co-delivery of the two genes would lead to biochemical rescue of the co-
transduced fibers, and mitigation of the immunostimulatory effect of dystrophic muscle.  
Consistent with our model, co-injection of the two vectors statistically significantly lowered the 
serum antibodies against β-galactosidase, even though twice as much AAV was injected into 
these animals.  Importantly, the biochemical rescue did not completely ablate the immune 
response to the marker gene, but only attenuated it.   
Interpreting these findings together with previous data, the bacterial β-galactosidase 
marker protein is probably a particularly stringent test of the potential immunostimulatory effect 
of dystrophic muscle.  Delivery to dystrophic muscle of therapeutic genes, even those that are 
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 from human into murine muscle, are likely less antigenic, and therefore lead to less severe 
immune response, and greater persistence than what we observed here (Li et al. 1999; Cordier et 
al. 2000; Xiao et al. 2000).  However, a corollary to our findings is that partial biochemical 
rescue of dystrophic muscle using highly truncated semi-functional proteins is likely to lead to a 
more aggressive immune response than would normal therapeutic proteins.  Human muscle is 
recognized to have a more stringent demand for the dystrophin protein when compared with 
murine muscle.  This is seen with Duchenne muscular dystrophy patients have a more severe 
phenotype and rapid disease progression when compared to the mdx mouse model’s disease 
progression (Bulfield et al. 1984; Sicinski et al. 1989; Partridge 1991; Infante and Huszagh 
1999; Hoffman 2001).  We anticipate that delivery of partially functional dystrophin proteins to 
patient muscle may require more attention to immune modulatory influences on transgene 
persistence, and subsequent gene delivery success. 
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Figure 23. AAV reporter construct shows greater transduction in normal versus dystrophic 
muscle, but the difference is mitigated by co-transduction with a therapeutic gene. 
Shown is graphical representation of a comparison (at 43 days post-injection) of β-galactosidase 
positive myofibers in the tibialis anterior of normal and β-sarcoglycan deficient animals injected 
with either an AAV containing LacZ alone or co-injected with an AAV containing LacZ and an 
AAV containing β-sarcoglycan.  Injection of AAV LacZ alone shows poor 
transduction/persistence in dystrophic muscle (Beta SG K/O AAV LacZ) compared to normal 
muscle (Normal AAV LacZ).  This difference is partially ablated by co-transduction of AAV 
LacZ and an AAV expressing a therapeutic gene, β-sarcoglycan (Beta SG K/O AAV LacZ and 
Beta SG).  This suggests that partial rescue of the biochemical defect mitigates the 
immunostimulatory properties of dystrophic muscle.   
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Figure 24.  β-sarcoglycan deficient animals that receive an injection with two viruses, 
express both viral transgenes in the same cells. 
Shown are photomontages of the entire TA muscle of a mouse co-injected with AAV LacZ and 
AAV β-sarcoglycan.  Panel A shows the TA stained with anti-α-sarcoglycan antibody to indicate 
which cells are sarcoglycan positive.  Panel B shows the TA stained with β-galactosidase.  The 
pattern of staining of myofibers that stain positive for the sarcoglycan (panel A) overlaps with 
those that are β-galactosidase positive (panel B).  This suggests that myofibers that were co-
injected with an AAV LacZ and AAV β-sarcoglycan, which are co-expressing the LacZ 
transgene and the β-sarcoglycan transgene, are protected from the dystrophic phenotype of the β-
sarcoglycan deficient muscle.   
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Figure 25.  Log-linear plot of serum antibody levels to β-galactosidase in all injected 
animals shows that β-sarcoglycan deficient mice elicit an immune response to the marker 
transgene, while normal mice elicit little to no immune response to the transgene. 
Shown is a log-linear plot of serum antibody titers in all animals injected with either AAV-LacZ 
alone or co-injected with both an AAV-LacZ and an AAV-β-sarcoglycan.  The plots are based 
on absorbance readings from the ELISA plates on diluted sera from mice.  All of the β-
sarcoglycan deficient mice elicit an immune response, while the normal mice sera exhibit similar 
patterns to the plate background readings.   
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Figure 26.  Log-linear plots of only the β-sarcoglycan deficient mice indicate there is 
quenching effect of antibody production to the LacZ transgene when the dystrophic muscle 
phenotype is corrected. 
Panel A shows a log-linear plot of serum antibody titers in β-sarcoglycan mice injected with 
either AAV-LacZ alone or co-injected with both an AAV-LacZ and an AAV-β-sarcoglycan, 
excluding the outlier.  Panel B shows the dilution values interpolated at an absorbance value of 1, 
which shows that the animals, which receive both AAV-β-sarcoglycan and AAV-LacZ, have a 
significantly lower serum dilution to have the same absorbance reading.   This indicates that 
correction of the dystrophic phenotype is accompanied by a significant decrease in antibody 
production to the LacZ transgene.    
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5.0 
 
Utilization of a 10-needle injection manifold for delivery to large muscle groups for the 
treatment of muscular dystrophies. 
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 5.1 Summary 
Recombinant adeno-associated virus (AAV) vector shows the most promise of any gene 
therapy vector for gene delivery to diseased muscle.  There have been a number of successful 
reports demonstrating use of AAV to deliver genes to rodent models of muscular dystrophy (Holt 
et al. 1998; Greelish et al. 1999; Li et al. 1999; Wang et al. 2000; Xiao et al. 2000; Cordier et al. 
2001).  However, there are some major hurdles that need to be overcome in order for gene 
delivery to show clinical efficacy in human trials.  One major hurdle is the limited packaging 
capacity of AAV (~5 kb), which is too small to package the gene causing the most common form 
of muscular dystrophy, Duchenne muscular dystrophy.  However, recent reports have shown 
biochemical efficacy of a highly truncated “mini” dystrophin gene containing only ~30% of the 
normal coding sequence (Wang et al. 2000).  A second hurdle is overcoming the problem of 
widespread delivery of AAV to muscle tissue, which accounts for ~30% of the body mass.  A 
recent promising report has described the use of Extra Corporeal Membrane Oxygenation 
(ECMO) system to isolate an entire limb of a rat and a hamster and perfuse it with histamine and 
the AAV vector (Greelish et al. 1999).   Whether this highly invasive protocol can be employed 
in higher vertebrates or humans remains to be seen.  In order to address the problem of large 
scale delivery in a controlled manner, we designed a multi-needle injection manifold to 
consistently deliver virus to a 2mm x 1cm area of muscle.  Using this injection manifold we have 
successfully delivered AAV to the quadriceps, the largest muscle group, in a hamster model of 
muscular dystrophy.    
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 5.2 Introduction 
The muscular dystrophies are a heterogeneous group of diseases which have traditionally 
been subdivided into various types based on the clinical distribution of muscle involvement, 
severity of muscle weakness, age of onset, or inheritance pattern.  The most common form is 
Duchenne muscular dystrophy (DMD), which is caused by a mutation in the dystrophin gene 
(Hoffman et al. 1987).  DMD affects approximately 1 in 3500 males in all populations studied to 
date, making it one of the most common genetically inherited diseases worldwide.  The limb-
girdle muscular dystrophies (LGMD), on the other hand, are a subset of the muscular dystrophies 
with much lower prevalence (1 in 100,000) (Emery 1991).  A molecular classification of the 
limb-girdle muscular dystrophies is now possible with the identification of the causative genes 
for most types.     
 Among the autosomal recessive limb-girdle muscular dystrophies, the 
sarcoglycanopathies are some of the best characterized at the molecular level.  Mutations in the 
sarcoglycan genes α-, β-, γ-, and δ- are responsible for LGMD 2D, 2E, 2C, and 2F, respectively 
(Hoffman 1999).  Clinically, patients with primary sarcoglycanopathies are indistinguishable 
from those with primary dystrophin abnormalities.   
Much of the research on the sarcoglycanopathies has been possible with the discovery 
that the Bio 14.6 hamster is a spontaneous loss-of-function animal model for δ-
sarcoglycanopathy (LGMD2F) (Nigro et al. 1997).  This model has served as an important test 
system in a series of genetic, biochemical, histological and functional studies that have proven 
the utility of recombinant AAV as a gene delivery vector for muscle (Holt et al. 1998; Greelish 
et al. 1999; Li et al. 1999; Xiao et al. 2000).   Animal models for the remaining 
sarcoglycanopathies have been developed as well (Duclos et al. 1998; Hack et al. 1998; Araishi 
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 et al. 1999; Coral-Vazquez et al. 1999; Liu and Engvall 1999; Durbeej et al. 2000), and have 
been used in gene therapy research using either adenovirus or adeno-associated virus (AAV) 
(Duclos et al. 1998; Allamand et al. 2000; Durbeej et al. 2000).   Despite recent advances, 
major obstacles stand in the way of using of viral vectors as effective modalities in the treatment 
of muscular dystrophies.  Muscles comprise approximately 30% of the body mass in humans, 
and introducing an AAV transgene to a number of different muscle groups presents a daunting 
challenge.  Intramuscular injection, for instance, will require multiple injections.  Additionally, 
many muscle groups are inaccessible to injection percutaneously, e.g. the diaphragm.  Given that 
muscle is a highly vascularized tissue, systemic delivery using the vascular route would appear 
to be a good means of delivery. Unfortunately, reports indicate that AAV vectors appear to have 
substantial liver-tropism in vivo, with most intravenously injected AAV vectors accumulating in 
liver with almost no expression in muscle (Ponnazhagan et al. 1997; Koeberl et al. 1999).  
Alternatively, access to the arterial side, bypassing the liver, might be a more appropriate 
approach.  A recently published report claims that administration of AAV vector through the 
arterial supply of an isolated limb via an Extra-Corporeal Membrane Oxygneation (ECMO) 
circuit resulted in widespread expression of the transgene in hamsters (Greelish et al. 1999). 
Unfortunately, the exact nature of the procedure and its consequences has not been adequately 
studied, including the potential risks of using histamine to induce endothelial permeabilization.   
We have developed a multi-needle injection manifold that we envision as a safer 
alternative for large-scale delivery of vectors to large areas of muscle.  Here, we report the 
successful delivery of a complementary gene construct, an AAV-δ-sarcoglycan vector, to the 
Bio14.6 hamster (δ-sarcoglycan deficient) quadriceps muscles.  
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 5.3 Materials and methods 
5.3.1 AAV vector production 
An AAV vector was produced containing the human cDNA for δ-sarcoglycan under control of a 
CMV promoter, as we have previously described (Li et al. 1999).  The human δ-sarcoglycan 
cDNA was amplified using the following primers: δ-SG-For (5’ 
TCCTTCAGAGCTGCTGCTCAGCACGCCC 3’) and δ-SG-Rev (5’ 
CCCGTTTGTTCATTGCCCATCAGGCC 3’).   The AAV was produced using a triple plasmid 
co-transfection method previously described (Xiao et al. 1998).  Viral titers were determined by 
DNA dot-blot analysis and found to be in the range of 2-5 x 1012 particles per mL.    
5.3.2 Viral delivery to muscle 
Bio 14.6 hamsters were purchased from Bio Breeders (Fitchburgh, MA).  Hamsters were 
anesthetized with an intraperitoneal administration of 2.5% Avertin (Aldrich, Milwaukee, WI) at 
a dose of ~20mL/kg body weight, prior to viral vector injection.  Each hamster received a 100 
µL intramuscular injection of AAV δ-sarcoglycan utilizing the injection manifold (10µl/needle).  
Each quadriceps was exposed by an incision in the leg of each animal prior to injection of AAV.   
5.3.3 10-needle injection manifold  
Hamilton (Reno, NV) constructed the custom 10-needle injection manifold.  The MicroLab 
501A dispenser is connected to ten 50 µL Hamilton glass syringes that each have a 12 inch 30 
gauge needle with a 30° bevel.  The needles are aligned using an aluminum needle holder such 
that all needles are 2 mm apart from one another in a 2 x 5 pattern covering a 2mm x 1 cm area 
(Figure 27).  
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 5.3.4 Western blot analysis 
Injected hamster quadriceps were dissected at 86 days post-injection, halved, then serially 
sectioned as follows.  One half of each quadricep was sectioned every 300 µm for a total of ~18 
regions covering a total of 5.4 mm.  Each of these regions of muscle sections were solubilized in 
100 µL of muscle solubilization buffer (10% SDS, 0.1 M Tris pH 8, 10 mM DTT) and boiled for 
2 min.  25 µL of this solution was then loaded onto a 10% SDS PAGE gel.  The gel was 
processed for western blotting as previously described.  The post-transfer gel was stained with 
Coomasie Blue to visualize the myosin heavy chain protein, which was used as a control for the 
amount of protein loaded and as an indicator for efficiency of transfer.  δ-sarcoglycan specific 
antibodies from Novocastra Laboratories (Newcastle, UK) were used for staining.   
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 5.4 Results 
 In our preliminary study (Li et al.  1999), we empirically observed the distance of AAV 
dissemination from a single needle injection point to be approximately 1 mm.  We therefore 
designed an injection manifold with the spacing of the needles at 2 mm apart.  The 10 needles 
cover a 2mm x 1 cm area, which is able to completely cover the largest muscle group of the 
hamster, the quadriceps.  The utilization of the MicroLab 501A from Hamilton Industries (Reno, 
NV) allows for specific control of injection speed and the volume of the vector being delivered 
in each needle (Figure 27).  Additionally, this injection manifold can be controlled with a foot 
pedal device allowing for more flexibility with the use of both hands during the procedure.   
 Using this device, we injected 5 Bio 14.6 hamsters in one quadriceps with a AAV-δ-
sarcoglycan vector at 10 µl/injection site (100 µl total; 2-5 x 1011 viral particles).  At 86 days 
post injection, the animals were sacrificed, and their quadriceps dissected and flash-frozen.  After 
serial sectioning the samples and immunostaining for δ-SG, we found consistent homogeneous 
staining of the entire quadriceps (Figure 28).  These results were confirmed by western blot 
analysis, which showed equal amounts of δ-sarcoglycan throughout the entire quadriceps of the 
Bio 14.6 hamster at approximately 3 times more than normal (Figure 29).   
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 5.5 Discussion 
Our results indicate that consistent, homogeneous, and long-term expression of a 
transgene vector over a wide area of muscle can be achieved using an evenly spaced multi-
needle injection manifold device.  The device, the design of which is detailed in this report, has 
many advantages.  First, the device provides a reproducible, accurate, and consistent method to 
deliver transgene vectors to wide areas of diseased muscle.  Second, the device utilizes 
removable, metal needles that can be autoclaved, preventing any cross contamination of the 
needles between experiments and/or animals.  If this device were to be utilized in human trials in 
the future, a larger needle platform and disposable needles would need to be used.  Third, the 
speed and amount of vector delivery can be precisely controlled.  Fourth, this device can be 
operated by a foot petal, freeing up both hands for ease of operation.  Lastly, this method should 
be considerably safer than the previously described ECMO delivery, and has yielded highly 
promising results.   
Some of the potential problems that can be encountered when using this manifold are the 
following.  First, while the manifold does correct for two-dimensional error by user, i.e. where 
the needles are placed in the muscle, it does not correct for the third-dimension of the muscle, i.e. 
how deep each injection is into the muscle.  Second, while theoretically there is no loss of vector 
during delivery, in reality there is always the potential that some of the vector will be lost by not 
being fully evacuated from the needle or the syringe.   
We envision the design concept of this device leading to the development of an increased 
number of needles for injection of human patients in a staggered injection schedule.  
Immunosuppressive agents could also be used so that readministration of more viral vectors 
could occur at a later date.  We would target those muscles from which the patient can derive the 
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 most benefit.  In the case of the limb-girdle muscular dystrophies, which present initially with 
proximal muscle weakness, we would target the limb muscles, allowing the patient to ambulate 
longer.   
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Figure 27.  Schematic and photograph of 10-needle injection manifold. 
Panel A shows a Schematic drawing of the 10-needle injection manifold.  Panel B is a picture of 
the actual 10-needle injection manifold, with foot pedal.  Panel C shows a close up photograph of 
the needle holder.   
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Figure 28. Widespread expression of δ-sarcoglycan via intramuscular injection using the 
10-needle injection manifold delivering an AAV containing δ-sarcoglycan.  
α-sarcoglycan staining of the Bio 14.6 hamster quadriceps after intramuscular injection using the 
10-needle injection manifold indicates that there is widespread expression of the transgene 
throughout the entire muscle section.   
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Figure 29.  Western blot analysis of δ-sarcoglycan deficient hamster quadriceps injected 
with an AAV containing the human δ-sarcoglycan gene using the 10-needle injection 
manifold shows consistent delivery throughout the entire muscle. 
Shown is a western blot where each well represents 250 µm of muscle, with all 18 wells 
covering a total of ~5400 µm of the quadriceps.  Lane 8 is a control human muscle using 
approximately the same amount of muscle.  Lane 20 is an uninjected control δ-sarcoglycan 
deficient hamster.  All lanes show more δ-sarcoglycan production than is seen in normal human 
muscle, with fairly consistent staining throughout the entire muscle.  The slight decrease in the 
staining toward the tendon may be due to smaller muscle diameter towards the tendon insertion.          
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Discussion 
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 6.1 Complex protein biochemistry alters efficacy of gene delivery 
Here I report the biochemical and histological rescue of both α- and β-sarcoglycan deficient 
mice with an AAV vector containing the corresponding sarcoglycan gene.  This was done in an 
effort to better understand the interactions of the sarcoglycan complex, as well as to advance 
progress in therapeutic gene delivery to the muscular dystrophies.  I was able to successfully 
deliver and express transgenes to complement both types of sarcoglycan deficiency.  While both 
α- and β-sarcoglycan delivery at early time points exhibited primary and secondary biochemical 
and histological correction of the correspondingly dystrophic muscle, only β-sarcoglycan AAV 
transduction resulted in long-term biochemical and histological rescue.  The results from the β-
sarcoglycan data are consistent with the data that were previously generated using δ-sarcoglycan 
AAV and the hamster model (Li et al. 1999, Xiao et al. 2000).  Our data is also consistent with a 
report on AAV gene complementation of γ-sarcoglycan deficiency in a mouse model (Cordier et 
al., 2000). 
The α-sarcoglycan data I obtained was not consistent with the other 3 sarcoglycans, as α-
sarcoglycan deficient mice, treated with an AAV containing the human α-sarcoglycan gene at 30 
days post-injection, exhibited large-scale loss of α-sarcoglycan positive cells.  Histological 
examination of injected muscle showed infiltration of immune cells in areas where α-
sarcoglycan positive fibers were located.  The immune infiltration was analyzed by 
immunophenotyping and was found to be primarily macrophages with some T- and B-cells.  We 
interpreted these results to indicate that macrophage infiltration was a secondary response to 
myofiber necrosis, due to over-expression of α-sarcoglycan and subsequent cytotoxicity. 
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 To test our hypothesis of α-sarcoglycan toxicity, we designed experiments to determine if the 
immune response was causative for the clearance of α-sarcoglycan positive fibers, or if it is not 
necessary for loss of α-sarcoglycan positive myofibers.  This was done by injecting α-
sarcoglycan and β-sarcoglycan expressing AAV into Severe Combined Immune-Deficient 
(SCID) mouse muscle; these mice lack T- and B-cells and therefore should lose transduced 
myofibers only if loss is mediated by cytotoxicity.  Since these mice have normal sarcoglycan 
expression, I was not able to monitor transgene sarcoglycan expression in muscle by 
immunofluorescence.  Instead I assayed for centrally nucleated cells as the endpoint; central 
nucleation is an accurate marker for the amount of myofiber degeneration/regeneration that has 
occurred.  The number of myofibers undergoing degeneration/regeneration in normal (non-
dystrophic) muscle is very small.  Comparison of the number of central nucleated fibers in SCID 
mice injected with either AAV α-sarcoglycan, AAV β-sarcoglycan or PBS showed that the AAV 
β-sarcoglycan and PBS groups did not have a statistically different number of centrally nucleated 
fibers, but the group injected with AAV α-sarcoglycan had statistically more centrally nucleated 
fibers than the other two groups.  These results suggest that over-expression of α-sarcoglycan 
causes cytotoxicity.  They also indicate that the immune response seen in the α-sarcoglycan 
deficient mice is likely secondary to the cytotoxic response, and does not reflect immune-
mediated loss of transduced myofibers. 
These in vivo results corroborate recent biochemical studies of the sarcoglycan complex.  
The current model of sarcoglycan complex assembly is that β-sarcoglycan nucleates the complex 
in the golgi, followed by the addition of both γ- and δ-sarcoglycan in either order, with α-
sarcoglycan addition completing the tetrameric complex (Noguchi et al. 2000) (Figure 19).  One 
explanation for apparent variable order of  γ- and δ-sarcoglycan attachment is that these two 
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 proteins are highly homologous and are probably the result of a relatively recent gene duplication 
event.  The hierarchical assembly of the complex appears in agreement with in vivo studies, 
where over-expression of α-sarcoglycan causes cytotoxicity while over-expression of β-
sarcoglycan, δ-sarcoglycan (from our previous results), and γ-sarcoglycan (Cordier et al. 2000) 
do not (Figure 20).  There are two possible models that we believe integrate the biochemical and 
in vivo AAV findings.  The first possibility is that α-sarcoglycan subunits inappropriately fill the 
 γ- or δ- binding sites on β-sarcoglycan, causing the formation of abnormal tetramers.  The βα2 
or βα3 complexes may form initially, but accumulate in the golgi or are unstable, leading to loss 
of the complex and eventual cytotoxicity (Figure 21).  Another possibility is that the over-
expression of α-sarcoglycan causes an incorrect order of assembly of the complex, with α-
sarcoglycan binding prematurely to β-sarcoglycan.  This premature binding could cause 
conformational changes in β-sarcoglycan, which could prevent binding of γ or δ-sarcoglycan.  
Again, the resulting complex might not be transported to the cell surface and could accumulate in 
the golgi, or may be unstable; each possibility may result in cytotoxicity (Figure 22).  However, 
with both of these models, there will be low levels of proper assembly of the sarcoglycan 
subunits that will form normal sarcoglycan complex, and only accumulation over time of the 
improper complexes will lead to cytotoxicity. 
There are additional explanations of our data that do not depend on the altered assembly 
of the complex.  First, I delivered the human α-sarcoglycan gene to a murine model, and the 
human protein product may not be sufficiently similar to the murine orthologue to assemble or 
function appropriately.  Consistent with this interpretation, the murine and human α-sarcoglycan 
proteins show the greatest sequence divergence, with α-sarcoglycan protein showing 88% 
identity between mouse and human, and β-sarcoglycan protein showing 95% identity (Appendix 
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 A, B).  In addition, α-sarcoglycan is distinct from the other three sarcoglycans in that the N 
terminus is extracellular, while the other three have intracellular N termini (Figure 2).  The 
signaling needed for correct post-translational processing and orientation in the membrane may 
have diverged sufficiently between the human so as to incorrectly process α-sarcoglycan.  The 
major argument against this explanation as the cause of cytotoxicity is the finding of successful 
short-term biochemical and histological rescue of α-sarcoglycan deficient muscle.  We believe 
that a lack of function of human α-sarcoglycan in murine muscle would most likely not show 
time-dependent loss of transduced fibers.  Also, our observation of cytotoxicity in SCID mice 
indicates that with co-expression of the murine α-sarcoglycan and human α-sarcoglycan, the 
human α-sarcoglycan has a dominant cytotoxic effect on transduced muscle, likely due to over-
expression (i.e. co-expression of murine α-sarcoglycan was not protective).   
A second potential reason for α-sarcoglycan induced cytotoxicity is that α-sarcoglycan 
contains a particularly large cytoplasmic domain relative to the other three sarcoglycans.  This 
cytoplasmic domain may be involved with protein-to-protein interactions, and over-expression of 
α-sarcoglycan could lead to inappropriate interactions of some intracellular factors.  However, 
the available data on the timing of AAV driven expression of transgenes may argue against this 
model.  Studies have shown that AAV expression levels are highest at 2 weeks post-injection 
(Vincent-Lacaze et al. 1999), and one would expect that the highest levels of expression of α-
sarcoglycan would lead to the most inappropriate protein interaction and therefore the highest 
level of cytotoxicity.  However, I observed biochemical and histological rescue of muscle at this 
2 week post-injection time point arguing against a model where cytotoxicity is caused by 
improper interaction of intracellular molecules.   
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 Finally, α-sarcoglycan is distinct from the other sarcoglycans in that there is a closely 
related molecule, ε-sarcoglycan, that is also expressed in skeletal muscle, and is thought to be 
somewhat interchangeable with α-sarcoglycan in the sarcoglycan complex.  The over-expression 
of α-sarcoglycan could result in the exclusion of ε-sarcoglycan from binding to the sarcoglycan 
complex, and this might mediate toxicity via a dominant-negative effect on ε-sarcoglycan 
function.  However, ε-sarcoglycan expression does not change (compensate) in α-sarcoglycan-
deficient mice (Liu and Engvall 1999), and immunostaining for the sarcoglycan complex showed 
that the other three sarcoglycan subunits (β-, γ-, or δ-) were not present at the membrane.  Taken 
together, these data suggest that ε-sarcoglycan does not play a protective or compensatory role in 
α-sarcoglycan deficiency.   
In conclusion, I have shown that delivery of closely related proteins by AAV can lead to 
very different outcomes, with complete, long-term rescue of muscle by β-, γ-, or δ-sarcoglycan, 
but significant cytotoxicity and muscle damage by α-sarcoglycan.  Therefore, there are aspects 
of protein biochemistry that do in fact alter efficacy of gene therapy, even in closely related 
biochemical defects.    
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 6.2 Disease pathology alters immune responses to transgenes in muscle   
Dystrophic muscle has many histological hallmarks, including fiber size variation, 
scattered areas of degeneration/regeneration, hypercontracted fibers, connective tissue 
proliferation, and cellular infiltration.  Each of the cellular pathologies has a potential to 
modulate the transduction rate and persistence of transgenes delivered to dystrophic muscle.  
Fiber size variation reflects the presence of both mature and immature myofibers, both of which 
show differential transduction by specific viral particles.  The different maturity of these fibers 
does not appear to affect AAV transduction as much as adenovirus transduction (Cao et al. 
2001).  Connective tissue proliferation is likely to inhibit the spread of virus in muscle.  
Degeneration/regeneration could lead to the loss of positive fibers, as they are degenerated with 
the regeneration of a fiber that does not contain the transgene.  In addition, degenerating fibers 
would allow for the cellular content of the myofibers, including the transgene product, to be 
released into the intercellular space where it would be surveyed by immune cells.    Immune cell 
infiltrate due to necrotizing myofibers may create a milieu that promotes an immune response to 
the delivered transgene.  The infiltrating bone marrow-derived cellular infiltrate will present 
antigens (Arahata and Engel 1984; Arahata and Engel 1988; Emslie-Smith et al. 1989), including 
those produced by the transgene.   In addition, myofibers in pathological muscle, such as 
hypercontracted fibers, express antigen-presenting molecules (Nagaraju et al. 1999) and become 
more efficient at antigen presentation.  Thus, a myofiber itself may present a transgene product 
as an antigen that can be recognized by activated T-cells in pathological muscle.   
We were particularly interested in the degeneration/regeneration followed by immune 
cell infiltration, as we hypothesized that this process would impart immunostimulatory properties 
to dystrophic muscle, and thus elicit more aggressive immune responses than normal muscle.  
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 We tested this hypothesis by injecting both normal muscle and dystrophic muscle (β-sarcoglycan 
deficient muscle) with an AAV containing a bacterial reporter gene (LacZ).  In agreement with 
our hypothesis, we found that the dystrophic muscle is considerably more prone to eliciting an 
immune response to the transgene, indicated by statistically fewer cells expressing the transgene 
(LacZ) 43 days post-injection, and by dramatic rises in serum titers of antibodies against the 
transgene.  Normal mice did not generate detectable antibody titers to the transgene and also 
showed persistent expression of the transgene at 43 days post injection.  We conclude that 
dystrophic muscle does indeed possess immunostimulatory properties.    
We further hypothesized that complementation of the biochemical defect in dystrophic 
myofibers could attenuate the immunostimulatory response; either due to a decrease in 
inflammatory cell infiltrate (mitigation of necrosis), or due to decreased antigen presentation by 
transduced myofibers, or both.  To test this, I injected both normal and β-sarcoglycan deficient 
mice with a combination of two AAV viruses, one carrying the LacZ reporter gene and the other 
a therapeutic β-sarcoglycan gene.  Indeed, even though I injected twice as many viral particles 
into the muscle in the co-transduction experiments, I found a 10 fold decrease in the immune 
response against the reporter gene.  This indicates that biochemical rescue of myofibers does 
mitigate the immunostimulatory response, either by decreasing necrosis and subsequent 
macrophage and T-cell infiltration, and/or by decreasing the antigen-presenting ability of rescued 
myofibers.   
I also measured the immune response using an ELISA assay to monitor the amount of 
antibody production in β-sarcoglycan deficient mice receiving a LacZ transgene.  A significantly 
higher antibody response to β-galactosidase was observed in the β-sarcoglycan deficient mice 
that received only AAV LacZ virus compared with the β-sarcoglycan deficient mice that 
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 received both a corrective AAV β-sarcoglycan virus and the AAV LacZ virus.  While the trend 
was clearly evident, statistical significance (p=0.010) was attained only when one statistical 
outlier was eliminated from the assay.  When the statistical outlier was included in the analysis, 
only partial significance was found (p=0.0545).  The outlier was defined statistically using the 
methods of Cook, i.e. calculation of a Cook’s distance statistic, and was from the group of β-
sarcoglycan deficient mice that received both the AAV LacZ and the AAV β-sarcoglycan.  
Importantly, this outlier was also the animal that exhibited a lower number of β-galactosidase 
positive cells relative to others in its group.  We attribute this data point outlier to variability in 
transduction efficiencies based upon intra-muscular injection techniques.  The ELISA data also 
suggest that antibody levels are correlated with the number of β-galactosidase positive cells, i.e. 
animals with higher antibody titers had a lower number of β-galactosidase positive fibers, 
whereas animals with lower antibody titers had a higher number of β-galactosidase positive 
fibers.  The normal mice did not vary significantly from the background readings of the ELISA 
plates, indicating that the normal mice did not show a significant antibody response to the β-
galactosidase reporter protein.  Again, these results indicate that dystrophic muscle itself can 
stimulate an immune response to the transgene.  In addition, disease muscle pathology can also 
alter gene transfer efficacy.  One consequence of these results is that a transgene that can fully 
biochemically and histologically rescue the biochemical defect will show less of an immune 
response against the transgene, while a transgene that only partially rescues a dystrophic muscle 
may still evoke a strong immune response.  
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 6.3 Large scale gene delivery 
The muscular dystrophies are among the most common and clinically devastating of the 
inherited monogenic disorders.  Worldwide, 1:3500 males are born with the Duchenne muscular 
dystrophy type alone.  Adeno-associated virus (AAV) has emerged as the most promising 
delivery vector to muscle.  However, with muscle consisting of a large portion (30%) of the body 
mass there needs to be major advances in large scale gene delivery if clinical efficacy of gene 
delivery can ever be achieved.  Here we present one step towards this goal with the development 
of a 10 needle-injection manifold for efficient and consistent gene delivery to a 2 mm x 1 cm 
region of muscle (the largest muscle group in the hamster).   
 Muscle is a highly vascularized tissue, which makes intravenous (IV) delivery of genes a 
promising route of administration.  However, reports have shown that IV delivery of AAV does 
not efficiently reach the muscle target tissue, but rather accumulates in the liver (Ponnazhagan et 
al. 1997).  Another group attempted to bypass the liver by delivering an AAV vector along with 
histamine using an Extra Corporeal Membrane Oxygenation (ECMO) system, which isolated the 
blood supply for an entire limb (Greelish et al. 1999).  While this report does show considerable 
promise, there are major risks associated with the use of an ECMO model for perfusion of an 
entire limb.  In addition, there is an inherent danger of using histamine to induce endothelial 
permeabilization.  We believe that the injection manifold method is a safer and more predictable 
way by which to deliver genes.    
The injection manifold provides a consistent and reproducible means of vector delivery.  
We have shown expression of the transgene at 3 times the normal level as compared to human 
control muscle, and delivery of the transgene and expression level was consistent throughout the 
entire quadriceps.  The stable needle holder ensures 2 mm spread between each of the needles for 
 137
 consistent injections.  The footpad operation of the injection enables the use of both hands during 
the injection procedure.  The concept of this device could be further expanded to develop a 
method to deliver genes to all muscles in human patients in a safe and effective manner by 
increasing the number of needles for injection. 
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 6.4 Future Studies 
 The biochemical and histological rescue of β-sarcoglycan deficient mouse muscle with 
AAV-mediated gene delivery of the β-sarcoglycan gene has led us to pursue a collaboration with 
a company to produce AAV for clinical trials.  We hope to test the safety of this delivery method 
for therapeutic purposes in humans.  In addition, based on our results with the successful use of 
the multi-needle injection manifold, we are also proposing to use the 10-needle injection 
manifold for delivery of the β-sarcoglycan AAV vectors in the safety trials, to test this delivery 
method in human muscle.    
Based on our results, we hypothesize that the cytotoxicity seen with the AAV gene 
delivery of α-sarcoglycan was due to its over-expression because of the use of the CMV 
promoter to drive expression.  We will test the effectiveness of using the α-sarcoglycan 
endogenous promoter for gene expression, in the hopes that the production of α-sarcoglycan is 
diminished to normal levels of expression, which should not cause cytotoxicity and therefore 
have therapeutic potential.  In addition, we hope to determine what sarcoglycan subunits are 
present in animals that are over-expressing α-sarcoglycan, and to help better define which of the 
potential models for α-sarcoglycan cytotoxicity may be correct.  We will attempt to accomplish 
this by immunoprecipitate the sarcoglycan complex from muscle that has been injected with an 
AAV α-sarcoglycan.   
Our results with immune cell involvement of the clearance of AAV α-sarcoglycan 
expressing myofibers has led us to pursue some other experiments to better define some specific 
types of immune cells involved.  It is necessary to determine if macrophages are present in the 
SCID mice receiving an injection of AAV α-sarcoglycan, so experiments will be performed to 
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 quantitated macrophages in the injected SCID mice.  We also would like to determine what role 
natural killer (NK) cells are playing in the clearance of α-sarcoglycan positive fibers from cells 
that are over-expressing α-sarcoglycan, NK beige mice will be injected with an AAV α-
sarcoglycan and studied for evidence of cytotoxicity.  Also an α-sarcoglycan deficient mouse 
muscle injected with AAV α-sarcoglycan will be analyzed for the presence of NK cell infiltrate.   
Our findings of the immunostimulatory effect that dystrophic muscle has on delivered 
transgenes, has led us to propose the experiment of delivering the truncated “micro-dystrophin” 
genes using an AAV vector to a higher vertebrate model, such as the dog, prior to any safety 
testing in human patients.  Finally, to help further understand the immunostimulatory properties 
of dystrophic muscle, we will also attempt to determine, with expression profiling, the role of 
antigen presentation in the dystrophic muscle receiving a marker transgene.     
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Appendix A 
 
Mouse α-sarcoglycan vs. human α-sarcoglycan 
 
Percent Similarity: 90.698   Percent Identity: 88.889 
 
        Match display thresholds for the alignment(s): 
                    | = IDENTITY 
                    : =   2 
                    . =   1 
 
red   = N-terminal signal sequence  
green = N-linked glycosylation 
blue  = Transmembrane domain 
 
                    .         .         .         .         . 
       1 maaavtwipllagllaglrdtkaqqttlhllvgrvfvhplehatflrlpe 50 
         ||  . | |||  ||||| ||.||||||| |||||||| |:| ||| ||| 
       1 maetlfwtpllvvllaglgdteaqqttlhplvgrvfvhtldhetflslpe 50 
                  .         .         .         .         . 
      51 hvavpptvrltyhahlqghpdlprwlhytqrspynpgflygsptpedrgy 100 
         |||||| | :|||||||||||||||| ||||||:.||||||| ||||||  
      51 hvavppavhityhahlqghpdlprwlrytqrsphhpgflygsatpedrgl 100 
                  .         .         .         .         . 
     101 qvievtaynrdsfdttrqrlllligdpegprlpyqaeflvrshdveevlp 150 
         ||||||||||||||||||||.| ||||||| ||||||||||||| ||||| 
     101 qvievtaynrdsfdttrqrlvleigdpegpllpyqaeflvrshdaeevlp 150 
                  .         .         .         .         . 
     151 ttpanrfltalgglwepgelqllnitsaldrggrvplpiegrkegvyikv 200 
         .|||.|||.|||||||||||||||:||||||||||||||||||||||||| 
     151 stpasrflsalgglwepgelqllnvtsaldrggrvplpiegrkegvyikv 200 
                  .         .         .         .         . 
     201 gsatpfstclkmvaspdsyarcaqgqppllscydtlaphfrvdwcnvslv 250 
         |||.||||||||||||||:||||||||||||||||||||||||||||.|| 
     201 gsaspfstclkmvaspdsharcaqgqppllscydtlaphfrvdwcnvtlv 250 
                  .         .         .         .         . 
     251 dksvpepldevptpgdgilehdpffcppteatdrdfltdalvtllvpllv 300 
         ||||||| ||||||||||||||||||||||| ||||| |||||||||||| 
     251 dksvpepadevptpgdgilehdpffcppteapdrdflvdalvtllvpllv 300 
                  .         .         .         .         . 
     301 allltlllayimcfrregrlkrdmatsdiqmfhhcsihgnteelrqmaas 350 
         ||||||||||:|| |||||||||:||||||| |||.|||||||||||||| 
     301 allltlllayvmccrregrlkrdlatsdiqmvhhctihgnteelrqmaas 350 
                  .         .         .        
     351 revprplstlpmfnvrtgerlpprvdsaqmplildqh 387 
         ||||||||||||||| |||||||||||||.||||||| 
     351 revprplstlpmfnvhtgerlpprvdsaqvplildqh 387 
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Appendix B 
 
Mouse β-sarcoglycan vs. human β-sarcoglycan 
 
 
Percent Similarity: 95.912   Percent Identity: 94.969 
 
        Match display thresholds for the alignment(s): 
                    | = IDENTITY 
                    : =   2 
                    . =   1 
 
green = N-linked glycosylation 
blue  = Transmembrane domain 
 
                  .         .         .         .         . 
       1 maaaaaaaaateqqgsngpvkksmrekaverrnvnkehnsnfkagyipid 50 
            ||||||| ||| |||||||||||||||||.||||||||||||||||| 
       1 ..maaaaaaaaeqqssngpvkksmrekaverrsvnkehnsnfkagyipid 48 
                  .         .         .         .         . 
      51 edrlhktglrgrkgnlaicvivllfilavinllitlviwavirigpngcd 100 
         |||||||||||||||||||||:||||||||||:||||||||||||||||| 
      49 edrlhktglrgrkgnlaicviillfilavinliitlviwavirigpngcd 98 
                  .         .         .         .         . 
     101 smefhesgllrfkqvsdmgvihplykstvggrrnenlvitgnnqpivfqq 150 
         |||||||||||||||||||||||||||||||||||||||||||||||||| 
      99 smefhesgllrfkqvsdmgvihplykstvggrrnenlvitgnnqpivfqq 148 
                  .         .         .         .         . 
     151 gttklsveknktsitsdigmqffdprthnilfstdyethefhlpsgvksl 200 
         |||||||| |||||||||||||||||| |||||||||||||||||||||| 
     149 gttklsvennktsitsdigmqffdprtqnilfstdyethefhlpsgvksl 198 
                  .         .         .         .         . 
     201 nvqkasteritsnatsdlnikvdgraivrgnegvfimgktiefhmggdve 250 
         |||||||||||||||||||||||||||||||||||||||||||||||..| 
     199 nvqkasteritsnatsdlnikvdgraivrgnegvfimgktiefhmggnme 248 
                  .         .         .         .         . 
     251 lkaensiilngtvmvsptrlpssssgdqsgsgdwvryklcmcadgtlfkv 300 
         |||||||||||.|||| ||||||||||| ||||||||||||||||||||| 
     249 lkaensiilngsvmvsttrlpssssgdqlgsgdwvryklcmcadgtlfkv 298 
                  .         . 
     301 qvtghnmgcqvsdnpcgnth 320 
         |||  |||||:||||||||| 
     299 qvtsqnmgcqisdnpcgnth 318 
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Appendix C 
 
Mouse γ-sarcoglycan vs. human γ-sarcoglycan 
 
 
 
Percent Similarity: 87.629   Percent Identity: 83.849 
 
        Match display thresholds for the alignment(s): 
                    | = IDENTITY 
                    : =   2 
                    . =   1 
 
green = N-linked glycosylation 
blue  = Transmembrane domain 
 
                   .         .         .         .         . 
       1 mvreqyttvtegthierpenqhiykigiygwrkrclylfvllllailvvn 50 
         |||||||| |||  |||||||::||||||||||||||||||||| ||||| 
       1 mvreqyttategicierpenqyvykigiygwrkrclylfvlllliilvvn 50 
                  .         .         .         .         . 
      51 laltiwilkvmwfspigmghlhvtadglrlegeseflfplyakeirsrvd 100 
         ||||||||||||||| ||||| || |||||||||||||||||||| |||| 
      51 laltiwilkvmwfspagmghlcvtkdglrlegeseflfplyakeihsrvd 100 
                  .         .         .         .         . 
     101 sslllqstqnvtvsarnsegevtgrvkvgaqmvevqsqhfqinsedgkpl 150 
         |||||||||||||.|||||||||||.||| .|||||.| ||||| ||||| 
     101 sslllqstqnvtvnarnsegevtgrlkvgpkmvevqnqqfqinsndgkpl 150 
                  .         .         .         .         . 
     151 fsaeeqdvvvgtgrlrvtgpegalfehsvetplvradpfqdlrlesptrs 200 
         |. :|.:||||| :|||||||||||||||||||||||||||||||||||| 
     151 ftvdekevvvgtdklrvtgpegalfehsvetplvradpfqdlrlesptrs 200 
                  .         .         .         .         . 
     201 lsmdaprgvhvkanagklealsqmdiilqssegvlvldaetvgltklkqg 250 
         ||||||||||:.|.|||:||||||||:  ||:|.|||||||| | || || 
     201 lsmdaprgvhiqahagkiealsqmdilfhssdgmlvldaetvclpklvqg 250 
                  .         .         .         .  
     251 tqgpagssngfyeicacpdgklylsmagevttceehshvcl 291 
         | ||.|||   |||| |||||||||.||  |||:||||:|| 
     251 twgpsgssqslyeicvcpdgklylsvagvsttcqehshicl 291 
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Appendix D 
 
Hamster δ-sarcoglycan vs. human δ-sarcoglycan 
 
 
 
Percent Similarity: 96.540   Percent Identity: 94.810 
 
        Match display thresholds for the alignment(s): 
                    | = IDENTITY 
                    : =   2 
                    . =   1 
 
green = N-linked glycosylation 
blue  = Transmembrane domain 
 
                  .         .         .         .         . 
       1 .mpqeqyshhrstmpssegphiykvgiygwrkrclyffvlllmililvnl 49 
          ||||||.||||||| | || :|||||||||||||||||||||||||||| 
       1 mmpqeqythhrstmpgsvgpqvykvgiygwrkrclyffvlllmililvnl 50 
                  .         .         .         .         . 
      50 amtiwilkvmnftidgmgnlritekglklegdseflqplyakeiqsrpgn 99 
         ||||||||||||||||||||||||||||||||||||||||||||||.||| 
      51 amtiwilkvmnftidgmgnlritekglklegdseflqplyakeiqsqpgn 100 
                  .         .         .         .         . 
     100 alyfksarnvtvnilndqtkvltrlvtgpkaveaygkkfevktvsgkllf 149 
         |||||||||||||||||||||||.|:|||||||||||||||||||||||| 
     101 alyfksarnvtvnilndqtkvltqlitgpkaveaygkkfevktvsgkllf 150 
                  .         .         .         .         . 
     150 saddnevvvgaerlrvlgaegtvfpksietpnvradpfkelrlesptrsl 199 
         |||.|||||||||||||||||||||||||||||||||||||||||||||| 
     151 sadnnevvvgaerlrvlgaegtvfpksietpnvradpfkelrlesptrsl 200 
                  .         .         .         .         . 
     200 vmeapkgveinaeagnmeatcrselrleskdgeikldaakiklprlprgs 249 
         ||||||||||||||||||||||.||||||||||||||||||:||||| || 
     201 vmeapkgveinaeagnmeatcrtelrleskdgeikldaakirlprlphgs 250 
                  .         .         .         . 
     250 ytptgtrqkvfevcicangrlflsqagtgstcqintsvcl 289 
         ||||||||||||:|:|||||||||||| |||||||||||| 
     251 ytptgtrqkvfeicvcangrlflsqagagstcqintsvcl 290 
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